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A miscarriage as a pregnancy outcome resulted related to a high prevalence of de-
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riages was, the worse the current state of mood was and the higher the frequency 
of a psychiatric diagnosis. The use of hormonal contraception was not associated 
with adverse psychological status or depressive symptoms or disorders, and no 
effect of different hormonal compounds was detected. Finally, a high prevalence 
of depressive and anxiety disorders emerged in connection with the menopausal 
transition, and current use of hormone therapy was associated with worse psy-
chological well-being or mental health in perimenopausal and postmenopausal 
women. 
In general, psychological well-being and mental health seem to be related to 
reproductive events in women.
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Abstract
Elena Toffol. Mental health and reproductive health in women. National Institute 
for Health and Welfare (THL). Research 106. 88 pages. Helsinki, Finland 2013.
ISBN 978-952-245-897-1 (printed); ISBN 978-952-245-898-8 (pdf)
This research aims at studying the relationship between mental health and reproduc-
tive features in women. The epidemiology and phenomenology of many psychiatric 
disorders differ between genders, with depressive and anxiety disorders, as well as at-
tempted suicide, being more common in women, and completed suicide, personality 
disorders and substance use disorders, in men. It is plausible that (endogenous and ex-
ogenous) gonadal hormones and reproductive events contribute to this pattern.
Data on women who participated in two Finnish population-based studies 
(Health 2000 and FINRISK 1997, 2002 and 2007) were analyzed. Data were collected 
through face-to-face interviews, self-administered questionnaires and health exami-
nations. Different structured (BDI-21, BDI-13, GHQ-12, CIDI) and non-structured 
tools were used to assess mental health and psychological well-being. Study I focused 
on the association between mental health and miscarriage, by history and number; 
Studies II and III focused on the relationship with use of hormonal contraception (ei-
ther oral or intrauterine) and its duration; Study IV concentrated on the associations 
between mental health and hormone therapy in perimenopausal and postmenopau-
sal women.  
Study I showed that a miscarriage as a pregnancy outcome was related to a high 
prevalence of depressive disorders, and to more severe depressive or anxiety symptoms 
compared with other pregnancy outcomes. Moreover, the higher the number of mis-
carriages was, the worse the current state of mood was and the higher the frequency 
of a psychiatric diagnosis.
Studies II and III revealed that the use of hormonal contraception was not asso-
ciated with adverse psychological status or depressive symptoms/disorders. Addition-
ally, no effect of different hormonal compounds was detected.
The main finding in Study IV was the high prevalence of depressive and anxiety 
disorders among women in connection with the menopausal transition. Moreover, in 
this group, an association between current use of hormone therapy and worse psycho-
logical well-being or mental health was detected.
The results of this study support the hypothesis of an association between psy-
chological well-being and reproductive features in women. The importance of consid-
ering reproductive health and events when assessing psychological status and mental 
health in women is discussed.
Keywords: mental health, depression, anxiety, women, reproduction, miscarriage, hor-
monal contraception, hormone therapy.
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tiivistelmä
Elena Toffol. Mental health and reproductive health in women. [Naisten 
mielenterve-ys ja lisääntymisterveys] Terveyden ja hyvinvoinnin laitos (THL). 
Tutkimus 106. 88 sivua. Helsinki, Finland 2013.
ISBN 978-952-245-897-1 (painettu); ISBN 978-952-245-898-8 (pdf)
Tässä tutkimuksessa tarkastellaan naisten mielenterveyden ja lisääntymisterveyden 
välistä suhdetta. Monet psykiatriset sairaudet ja oireet ilmenevät eri lailla sukupuol-
ten välillä, esimerkiksi masennustila ja ahdistusoireet ovat yleisempiä naisilla, kun si-
tä vastoin itsemurhat sekä persoonallisuus- ja päihdehäiriöt ovat yleisempiä miehil-
lä. On todennäköistä, että sukurauhashormonit ja lisääntymistapahtumat vaikuttavat 
mielenterveydessä ilmeneviin eroihin.
Naisten tutkimusaineistona käytettiin kahta suomalaista väestötutkimusta (Ter-
veys 2000 ja FINRISK 1997, 2002, 2007). Tämä aineisto koostui henkilökohtaisis-
ta haastatteluista, kyselylomaketiedoista ja terveystarkastusmittauksista. Mielenter-
veyden ja hyvinvoinnin arvioinnissa käytettiin sekä strukturoituja (BDI-21, BDI-13, 
GHQ-12, CIDI) että ei-strukturoituja menetelmiä. Ensimmäinen tutkimus koski mie-
lenterveyden ja keskenmenojen sekä niiden määrän välistä suhdetta. Toisessa ja kol-
mannessa tutkimuksessa tarkasteltiin mielenterveyden ja hormonaalisten (suun kaut-
ta nautittavien tai kohdunsisäisten) ehkäisykeinojen käytön sekä ehkäisyn keston 
välistä suhdetta. Neljäs tutkimus keskittyi mielenterveyden ja hormonikorvaushoidon 
välisiin yhteyksiin vaihdevuosi-ikäisillä ja vanhemmilla naisilla.
Ensimmäinen tutkimus osoitti että keskenmenon kokeneilla masennus oireet ja 
häiriöt olivat yleisiä. Tämän lisäksi keskenmeno yhdistyi vakavampiin mielentervey-
den häiriöihin verrattuna muihin raskauden lopputuloksiin. Mitä enemmän kesken-
menoja oli, sitä todennäköisempiä olivat psyykkiset oireet tai mielenterveyden häiriöt.
Toinen ja kolmas tutkimus osoittivat, että hormonaalisen ehkäisyn käyttö ei ol-
lut yhteydessä psyykkiseen pahoinvointiin tai masennusoireisiin. Eri hormoniyhdis-
teet eivät tässä suhteessa eronneet toisistaan.
Neljännen tutkimuksen päälöydös oli se, että masennus- ja ahdistuneisuushäiri-
öt olivat yleisiä vaihdevuosi-ikäisillä naisilla. Lisäksi tässä ryhmässä hormonikorvaus-
hoidon käyttö oli yhteydessä psyykkiseen pahoinvointiin.
Tämän tutkimuksen tulokset tukevat hypoteesia, että naisten lisääntymisterveys 
vaikuttaa psyykkiseen hyvinvointiin. Lisääntymisterveyttä edistämällä voidaan mah-
dollisesti edistää myös mielenterveyttä.
Avainsanat: mielenterveys, masennus, ahdistus, naiset, lisääntymisterveys, keskenme-
no, hormonaalinen ehkäisy, hormonihoito.
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Riassunto
Elena Toffol. Mental health and reproductive health in women. [Salute mentale e 
salu-te riproduttiva nella donna]. Terveyden ja hyvinvoinnin laitos (THL). Ricerca 
106. 88 pagine. Helsinki, Finlandia 2013.
ISBN 978-952-245-897-1 (formato cartaceo); ISBN 978-952-245-898-8 (formato pdf)
Lo scopo di questo studio è di esaminare la relazione tra salute mentale e caratteri-
stiche riproduttive nella donna. L’epidemiologia e la fenomenologia di molti disturbi 
psichiatrici è significativamente diversa tra uomo e donna. In particolare, la prevalen-
za dei disturbi depressivi e d’ansia, così come dei tentativi di suicidio, è più elevata tra 
le donne; d’altra parte, il suicidio, ma anche i disturbi di personalità e i disturbi da uso 
di sostanze, sono più comuni tra gli uomini. Si può ipotizzare che queste differenze di 
genere siano correlate all’influenza degli ormoni gonadici (sia endogeni che esogeni) e 
agli eventi connessi alla riproduzione.
In questa ricerca si sono analizzati i dati raccolti in Finlandia nel corso di due stu-
di di popolazione (Health 2000 e FINRISK 1997, 2002 e 2007). I dati sono stati raccolti 
attraverso questionari auto- ed etero-somministrati, interviste vis-à-vis e visite medi-
che. Il benessere psicologico e la salute mentale sono stati esaminati utilizzando stru-
menti di valutazione strutturati (BDI-21, BDI-13, GHQ-12, CIDI) e non strutturati. 
Lo Studio I si è focalizzato sull’associazione tra salute mentale e presenza in anamne-
si di aborto spontaneo, singolo o multiplo. Gli Studi II e III si sono occupati della rela-
zione tra salute mentale o benessere psicologico, e uso di contraccettivi ormonali (orali 
e/o intrauterini) e sua durata; lo Studio IV si focalizza sull’associazione con l’impiego 
di terapia ormonale sostitutiva in peri- e post-menopausa. 
I risultati dello Studio I hanno rivelato che l’aver un aborto spontaneo in anam-
nesi si associava con una maggior prevalenza, rispetto ad altri esiti di gravidanza, di 
sintomi e disturbi depressivi ed ansiosi. Sono inoltre emersi un peggioramento dell’u-
more ed una maggior frequenza di diagnosi psichiatriche all’aumentare del numero 
di aborti spontanei.
Gli Studi II e III hanno evidenziato che l’uso di contraccettivi ormonali non è as-
sociato ad un peggior stato di benessere psicologico né ad un aumentato rischio di 
manifestare sintomi e/o disturbi depressivi. Anche la valutazione dei diversi composti 
non ha evidenziato differenze significative.
Il principale risultato dello Studio IV è l’elevata prevalenza di disturbi depressivi 
ed ansiosi durante il periodo di transizione menopausale. In questo studio l’uso attua-
le di una terapia ormonale sostitutiva è risultato associato con una maggior compro-
missione della salute mentale, nonché con un peggior stato di benessere psicologico 
in generale.
I risultati di questa ricerca sono in linea con l’ipotesi iniziale, ovvero dell’esistenza 
di un’associazione tra benessere psicologico e caratteristiche riproduttive nella donna. 
Alla luce di questi risultati si è ribadita l’importanza di effettuare un’attenta valutazio-
12 THL – Research 106 ♦ 2013
ne della salute riproduttiva in generale e degli eventi della vita riproduttiva in partico-
lare ad ogni donna che manifesti sintomi o disagio psicologico.
Parole chiave: salute mentale; depressione; ansia; donne; riproduzione; aborto sponta-
neo; contraccezione ormonale; terapia ormonale sostitutiva.
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1 Introduction
A marked gender difference exists in the epidemiology and phenomenology of many 
psychiatric disorders. In particular, mood and anxiety disorders are known to be more 
common (and more commonly reported) in women than in men (Kuehner, 2003; 
Wittchen et al., 2011). This is especially true in the period of time that encompasses 
the fertile life of women, i.e. from the menarche to the menopausal transition. A spe-
cific gender and age pattern does also exist for suicidal behavior, with completed sui-
cide being more common among old men, and attempted suicide among young wom-
en (Hawton, 2000).
A complex interaction between multiple factors, including individual personali-
ty traits, social background, culture and, not least, biology, is required to explain this 
phenomenon. Among others, hormones play an important role. In spite of a wide va-
riety of hormones that are known to impact on mental health (e.g., cortisol and thy-
roid hormones), the influence of gonadal hormones on mental health and psycholog-
ical well-being in general is not fully understood. However, given the multiple effects 
that estrogens and progesterone exert on the central nervous system from the fetal 
stage onward, it is plausible that they at least contribute to the etiology, phenomenol-
ogy and epidemiology of psychiatric disorders.
Compared to men, women exhibit marked fluctuations in the levels of gonad-
al hormones during their fertile life. In addition, since reproductive events are so ob-
viously connected with social, psychological and physiological phases in women, it is 
important to understand the relationship between mental health, gonadal hormones 
and reproductive events.
Reproductive events include puberty, menstrual cycle, pregnancy and meno-
pause, but also pregnancy outcomes such as spontaneous and induced abortions, and 
exogenous gonadal hormones in the form of hormonal contraception and hormone 
replacement therapy. It is reasonable to assume that all these are able to influence 
women's mental health, both because of their psychological and social significance, as 
well as because of their biological effects on the central nervous system.
The social, psychological and biological effects of the above-mentioned factors 
can not be clearly disentangled. Nevertheless, trying to understand the way reproduc-
tive life is related to mental health and psychological well-being is a preliminary step 
to further investigating the underlying mechanisms that regulate such a complex as-
sociation.
This is particularly meaningful nowadays, when depressive and anxiety disorders 
that are more prevalent in women have an increasing social and economic impact 
(WHO, 2008).
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2 Review of the literature
2.1 Psychopathology: gender differences in  
 epidemiology and phenomenology
A significant proportion of psychiatric disorders are more prevalent in women than 
in men (Wittchen et al., 2011). The main exceptions are substance use disorders, psy-
chotic disorders and personality disorders, which are more common in men. Gender 
differences also exist with regard to the clinical presentation, treatment response and 
outcome of several mental disorders (Table 1).
2.1.1 Mood disorders in women: epidemiology and  
 phenomenology 
A recent study that sought to establish the 12-month prevalence of mental disorders 
in Europe found depression to be the most relevant contributor to the burden of dis-
ease in women (and alcohol abuse in men). The same study reported F:M ratios of 2.3 
and 1.2 for major depression (age range: 14 years and older) and bipolar disorder (age 
range: 18–65 years), respectively. Furthermore, in 2011, a total of 30.3 million people 
suffered from major depression and altogether 3.0 million from bipolar disorder in 
Europe (Wittchen et al., 2011). Even though there are no major gender differences in 
the incidence or in the clinical presentation or treatment response of bipolar I disor-
der, bipolar II/hypomania seems to be more common in women than in men (Di Flo-
rio & Jones, 2010). Also, there is clear evidence of an increased risk of recurrence/re-
lapse in the postpartum period (Jones & Craddock, 2005; Di Florio et al., 2013), and 
women with bipolar disorder complain of menstrual irregularity and premenstrual 
mood worsening (Blehar et al., 1998; Rasgon et al., 2003), as well as mood lability in 
connection with the perimenopausal transition.
In addition to differences in the prevalence rates, differences in the onset, course 
and phenomenology of mood disorders also exist between men and women. With re-
gard to major depressive disorder (MDD), women usually present with a younger age 
of onset, a greater risk of family history of affective disorders, and are more likely than 
men to experience atypical depression, sleep disturbances, psychomotor retardation, 
anxiety/somatic symptoms, distress (Kornstein et al., 2000a), as well as increased ap-
petite and weight gain (Williams et al., 1995; Frank et al., 1988). Moreover, women re-
spond to antidepressants differently compared to men, and the response depends on 
their reproductive stage. In fact, women usually show better response to antidepres-
sants (especially serotonin-noradrenaline reuptake inhibitors and selective serotonin 
reuptake inhibitors) than men (Khan et al., 2005), and women with chronic depres-
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sion, especially the young and premenopausal ones, tend to respond better and fast-
er to selective serotonin reuptake inhibitors (sertraline) than to tryciclic antidepres-
sants (imipramine) when compared with men. Conversely, postmenopausal women 
aged 40 years or older showed a similar response to imipramine and to sertraline (Ko-
rnstein et al., 2000b).
2.1.2 Anxiety disorders in women: epidemiology and  
 phenomenology
The category of anxiety disorders includes generalized anxiety disorder (GAD), social 
phobia, specific phobia, obsessive compulsive disorder (OCD), panic disorder (with 
or without agoraphobia) and post-traumatic stress disorder (PTSD). The F:M ratio of 
anxiety disorders as a whole is 2.5 in Europe, ranging from a 1.6 F:M ratio for OCD 
to a 3.1 F:M ratio for agoraphobia (Wittchen et al., 2011). Epidemiology, the clinical 
presentation and course of almost all anxiety disorders differs between genders. How-
ever, in general it seems that remission and relapse rates do not differ between men 
and women (Yonkers et al., 2003a).
In a national epidemiological survey in the USA the lifetime prevalence of GAD 
was 2.8% for men and 5.3% for women, with 1.2% and 2.7% 12-month prevalence 
rates for men and women, respectively (Vesga-López et al., 2008). Other epidemiolog-
ical data showed that, compared with men, women have higher 12-month prevalence 
rates of GAD all throughout their life-span. For men, the highest prevalence rates are 
found in the age group 25–34 years (with a prevalence rate of 3.2% vs. 5.0% in wom-
en). In women, the highest GAD prevalence rates have been observed in the age group 
45 years or older (prevalence rate of 6.3% vs. 0.9% in men) (Wittchen, 2002). Other 
studies (Yonkers et al., 2003a; Steiner et al., 2005; Simon et al., 2006) did report an ear-
lier age at GAD onset in women than in men. Vesga-López et al.'s survey (2008) re-
vealed several additional gender differences in the phenomenology of GAD, with men 
who were suffering from lifetime GAD being more likely to have a comorbid sub-
stance/alcohol use disorder and antisocial personality, and women being more like-
ly to suffer from a comorbid anxiety (panic disorder and specific phobia) or mood 
(MDD, dysthymia) disorder. Men used alcohol and drugs to alleviate anxious symp-
toms more often than women, while women were more fatigued, had difficulties in 
concentration, irritability, muscle tension, as well as other associated somatic symp-
toms. On the contrary, women were more likely to have a family history of depres-
sion and anxiety. However, there are some inconsistencies in respect to the response to 
GAD treatment: indeed, while Steiner and colleagues (2005) failed to find any signif-
icant difference in the response to 12 weeks sertraline, Simon et al. (2006) reported a 
poorer response to fluoxetine in women (in particular among those with GAD onset 
in old age) than in men.
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The gender differences with regard to social anxiety disorder/phobia resemble 
those observed in GAD (Xu et al., 2012), i.e., a F:M lifetime prevalence ratio of 1.4, co-
morbidity with alcohol and drug abuse, pathological gambling, conduct disorder and 
antisocial personality in men, and with mood and other anxiety disorders in wom-
en, and different symptoms across genders (women having worse psychosocial func-
tioning). Several gender differences also exist with regard to OCD, in particular in re-
spect to prevalence (higher in women than in men), age at onset (younger in men) 
and clinical presentation (type of onset, course of the disease and comorbidity) (Bo-
getto et al., 1999).
2.1.3 Suicidal behavior in women: epidemiology and  
 phenomenology
Suicidal behavior is a complex and multifactorial phenomenon ranging from suicid-
al thoughts, to suicidal ideation, attempted suicide and completed suicide. In gener-
al, completed suicide is almost worldwide more common in men with a M:F ratio of 
3.5:1 (WHO, 2001), while women are more likely to attempt suicide (Hawton, 2000) 
(Figure 1).
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Figure 1. Rates of self-harm injuries* and suicide** in USA, by age-group and 
gender. 
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A gender difference in the rates of completed suicide is evident already during 
childhood and adolescence in many countries (Gould et al., 2003; Steele & Doey, 2007; 
Pompili et al., 2012; Rhodes et al., 2012), with a significantly higher (3.7 times) rate of 
completed (but not attempted) suicide in males than in females aged 15–24 years in 
Europe (Värnik et al., 2009). The gender ratios in the epidemiology of completed sui-
cide vary with regard to age. In fact, the rates of completed suicide in the USA in 1998 
displayed an increase from 1.6/100 000 to 13.2/100 000, respectively, for children aged 
10 to 14 years and young adults aged 20 to 24 years. Moreover, during the shift from 
childhood to young adulthood, there was an increase of the gender ratio (boys:girls) 
from 2.6:1 to 6:1 (http://www.cdc.gov/nchs/nvss/mortality/hist290.htm).
Deliberate self-harm and attempted suicides are quite rare during childhood, but 
their rates increase significantly during adolescence. Among children younger than 15 
years, deliberate self-harm, usually impulsive and not aimed at death, is four to five 
times more common in girls than in boys (Hawton & Fagg, 1992; Hurry, 2000). In 
addition, girls are more likely to consider, plan and attempt suicide (Steele & Doey, 
2007). In general, the rates of attempted suicide and suicidal thoughts are higher in fe-
male adolescents, along with higher rates of psychopathology and internalizing prob-
lems (vs. more externalizing problems in male adolescents) (Kaess et al., 2011). Lewin-
sohn and colleagues (2001) found an increase in the risk of attempted suicide in girls 
aged 13 to 18 years, with a peak between 15 and 18 years, and a slight decrease between 
19 and 23 years of age. On the contrary, the risk of attempted suicide in boys increased 
during adolescence, with a peak at age 15 years, without reaching the female rates. In 
the same study the authors found that young women who had attempted suicide were 
more likely (than their non-suicidal counterparts) to have a history of previous suicid-
al ideation or attempts during adolescence, while this was not the case for young men. 
The authors also identified different risk factors for suicide attempt in young wom-
en and men.
The gender difference in the incidence and phenomenology of suicidal behav-
ior persists all throughout the life span. Middle-aged women who attempt suicide are 
more likely to suffer from anxiety disorders, and men from alcohol and substance 
abuse/dependence; furthermore, middle-aged women seem to make more impulsive 
suicidal attempts, while men have a higher lethal intent (Monnin et al., 2012). Gender 
differences also exist with respect to repetition of suicidal attempts, while male repeat-
ers are more likely to suffer from substance use disorders, and female repeaters from 
PTSD (Monnin et al., 2012).
Men and women appear to display different patterns of attitudes and beliefs 
against suicide (“reasons for living”), with young and middle-aged women report-
ing significantly higher scores on the reason-for-living scale in general, as well as for 
specific items (in detail: “fear of suicide”, “survival and coping beliefs”, “child-relat-
ed concerns”, “moral objections” and “responsibility to family”) than men (Dobrov et 
al., 2004; Pompili et al., 2007). Additionally, increasing age was found to be associat-
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ed with higher levels of responsibility to family, fear of suicide and fear of social disap-
proval in men but not in women (McLaren, 2011). 
Table 1. Gender differences in psychiatric disorders.
Overall 12-month 
prevalence 
(general 
population)
F:M ratio Source Phenomenology: 
F vs. M
MDD 6.9% 2.3 Wittchen et 
al., 2011*
• younger age at onset
• family history of affective disorders
• atypical depression
• sleep disturbances, psychomotor 
   retardation, anxiety/somatic 
   symptoms, distress, increased 
   appetite and weight gain
Bipolar disorder 0.9% 1.2 Wittchen et 
al., 2011
---
Panic 
disorder
1.8% 2.5 Wittchen et 
al., 2011
• older age at onset
• risk of agoraphobia and other 
   avoidance behaviors
• comorbid anxiety disorders
• longer duration of illness
Agoraphobia 2.0% 3.1 Wittchen et 
al., 2011
---
Social phobia 2.3% 2.0 Wittchen et 
al., 2011
• comorbid mood and other 
   anxiety disorders
• worse psychosocial functioning
GAD 1.7–3.4% 2.1 Wittchen et 
al., 2011
• younger age at onset
• comorbid  anxiety or mood 
   disorders
• fatigue, difficulties in concentra--
   tion, irritability, muscle tension
Specific 
phobias
6.4% 2.4 Wittchen et 
al., 2011
---
OCD 0.7% 1.6 Wittchen et 
al., 2011
• older age at onset
• clinical presentation (type of 
   onset, course of the disease and 
   comorbidity) 
• aggressive and contamination 
   obsessions and cleaning rituals
PTSD 1.1–2.9% 3.4 Wittchen et 
al., 2011
• longer persistence of symptoms
Suicidal
ideation
3.7% 1.2 Crosby et al., 
2011**
• more “reasons for living”
Attempted
suicide
0.5% 1.4 Crosby et al., 
2011
• comorbid anxiety disorders (vs. 
   alcohol and substance abuse/
   dependence in men)
• impulsive suicidal attempts
Completed 
suicide
0.01% 0.6 WHO, 
2008***
---
* catchment area: Europe; study design: systematic literature review + re-analyses of existing datasets.
** catchment area: USA; study design: national survey.
*** catchment area: all countries.
Abbreviations: Generalized Anxiety Disorder (GAD); Major Depressive Disorder (MDD); Obses-sive-Compulsive 
Disorder (OCD); Post-Traumatic Stress Disorder (PTSD).
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In general, it is not possible to rule out that the above described results from the 
literature review are partly affected by a report bias, with women being more prone to 
report and seek clinical help for depressive (especially somatic [Silverstein, 1999]) and 
anxiety symptoms. However, taken together these findings suggest that men and wom-
en differ with regard to their vulnerability to psychiatric symptoms and disorders, in-
cluding risk behaviors. In detail, it seems that the gender differences are not merely 
epidemiological, but also clinically evident in terms of temporal course and manifes-
tations of diseases.
2.2 Psychopathology in women’s  
 reproductive life
2.2.1 Premenstrual Syndrome and Premenstrual  
 dysphoric disorder
The Premenstrual Syndrome (PMS) is a general complex of severe, recurrent symp-
toms temporally related with the menstrual phase (Johnson, 1987). By definition, these 
symptoms occur seven to ten days before menses and end with their onset. Common 
symptoms of the PMS include anxiety, irritability, nervousness (sometimes leading to 
behavior detrimental to self, family and society), water and salt retention, abdominal 
bloating, mastalgia, craving for sweets, increased appetite, weight gain, palpitation, fa-
tigue, headache and the shakes. A less common but most severe syndrome is associated 
with depressive symptoms, insomnia, confusion and increased risk of suicide (Abra-
ham, 1983). Although the majority of women worldwide do present with some kind 
of premenstrual symptoms, around 13% to 18% of women of reproductive age have 
symptoms severe enough to be classified as PMS (Halbreich et al., 2002). The onset is 
usually with the menarche and in adolescence the symptoms frequently interfere with 
daily activities (Cleckner-Smith et al., 1998).
The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) defines the Premenstrual Dysphoric Disorder (PMDD) as a “depressive dis-
order not otherwise specified”, characterized by “physical symptoms associated with 
depressed mood or dysphoria, affective lability, decreased interest in usual activities, 
concentration difficulties, and others; symptoms are present for most of the time dur-
ing the last week of the luteal phase, begin to remit within a few days  after the onset of 
the follicular phase, and are absent in the week postmenses”. The estimated prevalence 
of PMDD ranges between 1% and 7% (Halbreich et al., 2002; Wittchen et al., 2002; 
Halbreich et al., 2003; Hong et al., 2012; Pilver et al., 2013).
There is a reciprocal association between PMS/PMDD and depressive/anxiety 
disorders: indeed, women with premenstrual dysphoric patterns are at increased risk 
for previous and subsequent episodes of MDD. A higher than 20% comorbidity rate 
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was found between PMDD and other mood disorders (Wittchen et al., 2002; Forrest-
er-Knauss et al., 2011), and a 44.7% comorbidity rate with anxiety disorders (Wittch-
en et al., 2002). On the other hand, women suffering from PMS/PMDD are more like-
ly to have a history of past MDD (Critchlow et al., 2001). The premenstrual period per 
se seems to be a risk for the exacerbation of pre-existent psychiatric symptoms or dis-
orders (Endicott & Halbreich, 1988), such as more prominent alcohol use in the case 
of alcoholism, symptom increase in the case of schizophrenia, or even higher rates of 
suicide attempts (Keye et al., 1986; Stout et al., 1986). In fact, women suffering from 
PMS/PMDD have an elevated risk of suicidal, aggressive or impulsive behavior (Endi-
cott & Halbreich, 1988; Wittchen et al., 2002), and 24% of women with PMDD report-
ed suicidal thoughts (Yonkers et al., 2003b).
2.2.2 Perinatal disorders
MDD during pregnancy is characterized by the same features than in other phases of 
women’s lives (American Psychiatric Association, 2000). It seems that around 18.4% 
of pregnant women experience depressive symptoms, and 12.7% suffer from a ma-
jor depressive episode (MDE) (Gavin et al., 2005) during pregnancy. Gotlib and col-
leagues (1989) found 25% of 360 pregnant women reporting depressive symptoms, 
and 10% suffering from MDD. Similarly, a 12.4% prevalence and a 2.2% incidence 
rate of depressive disorder (either minor or major) were detected during pregnancy in 
a recent longitudinal study (Banti et al., 2011). Marcus and colleagues (2003) reported 
a 20.4% rate of depressive symptoms among pregnant women screened in an obstet-
ric setting, and Evans et al. (2001) found in their cohort study more depressive symp-
toms during pregnancy than after the delivery itself, in line with the results report-
ed by Banti et al. (2011). However, it is likely that the real prevalence of MDD during 
pregnancy is underestimated due to misunderstanding of the symptoms (e.g. insom-
nia and altered appetite, thought to be normal reaction to pregnancy) and due to the 
stigma associated with mental illness.
Potential risk factors for depressive symptoms during pregnancy include sub-
stance and alcohol misuse and cigarette smoking during pregnancy, self-rated poor 
general health, being unmarried/without a partner, unemployed and having a lower 
education level (Marcus et al., 2003), having a family or personal past history of de-
pression, negative life events, lack of social (and partner) support, domestic violence 
and unintended pregnancy (Lancaster et al., 2010).
Anxiety disorders in general are quite common during pregnancy (Ross & 
McLean, 2006). In a survey on anxiety disorders and depression in the perinatal peri-
od, Sutter-Dallay and colleagues (2004) found 24% of participants suffered from anxi-
ety disorders, and 5.7% from MDD during pregnancy, with a significant proportion of 
comorbidity. Indeed, women suffering from anxiety disorders during pregnancy seem 
to be at elevated risk of developing depressive symptoms and/or disorders in the per-
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inatal period (Sutter-Dallay et al., 2004; Banti et al., 2011), and women suffering from 
depressive symptoms during pregnancy are at increased risk of developing postpar-
tum depression (in Lee & Chung, 2007).
Between 30% and 75% of live births are followed by post-partum blues, i.e. mild 
depressive symptoms with onset three to four days after delivery and lasting less than 
two weeks (O’Hara et al., 1990). Women who experience post-partum blues may 
themselves be at risk of developing depressive disorder during the first post-partum 
year (Bloch et al., 2005). Post-partum depression is characterized by symptoms of an 
MDE, but with onset within four weeks of delivery (American Psychiatric Association, 
2000). It may last up to six months post-partum or even longer. In general, it seems 
that the prevalence of depression during pregnancy or in the post-partum is rather 
similar to that in the general population, even if different rates are reported in the lit-
erature due to different diagnostic methods, different study designs (retrospective or 
prospective), and whether the studies distinguish between MDD in the post-partum 
and post-partum-onset depression (Gavin et al., 2005).
A systematic review (Gavin et al., 2005) reported a 19.2% prevalence of major 
or minor depression during the first 3 months postpartum, and Banti and colleagues 
(2011) reported a 9.6% prevalence rate of depressive disorder (either minor or major) 
in the 1-year postpartum, with an incidence rate of 6.8%. O’Hara and Swain (1996) 
found an average prevalence of post-partum depression in the general population of 
13%, and Georgiopoulos et al. (1999) found an 11.5% rate of depressive symptoms in 
a sample of 909 women assessed at week 6 post-partum; 5.3% had suicidal ideation in 
the previous week (1.4%) or infrequent thoughts of self-harm (3.9%).
Possible risk factors for post-partum depression include past history, as well as 
family history of psychological disorders; psychological disorders during pregnancy; 
previous postpartum depression; poor marital relationship; lack of social and spous-
al support (Seyfried & Marcus, 2003), as well as premenstrual irritability and/or mood 
changes (Sugawara et al., 1997). Possible protective factors include being breastfeeding 
and living with a spouse or a significant other (Yonkers et al., 2001).
The perinatal period is also an at-risk-period for other psychiatric illness, often 
associated with discontinuation of the pharmacological treatment. A severe post-par-
tum psychosis occurs in around 0.05% to 0.2% of new mothers, especially in women 
with a previous diagnosis of bipolar disorder (Gitlin & Pasnau, 1989; Jones & Crad-
dock, 2001; Di Florio et al., 2013); its onset is usually within four weeks after delivery.
Mental health and reproductive health in women
26 THL – Research 106 ♦ 2013
2.2.3 Perimenopausal disorders
Menopausal transition is known to be a sensitive period in a woman’s life, partly due 
to its broad psychological and social correlates and partly due to the considerable hor-
monal changes that it implies.
Even though the female predominance in the prevalence of depressive disorder 
seems to be slightly less evident after menopause (Weissman & Olfson, 1995), and the 
majority of women do not develop depressive symptoms or disorders in connection 
with the menopausal transition, nevertheless a subgroup of women seem to be more 
vulnerable to mood impairment during the perimenopause. Albeit some inconsisten-
cies (Vesco et al., 2007), studies report an increased risk (OR 1.8 to 2.9) of depressive 
symptoms (low mood, irritability and difficult concentration) and disorders in the pe-
rimenopause when compared with the premenopause (Freeman et al., 2004; Freeman 
et al., 2006), even in women with no history of past depressive disorder (Cohen et al., 
2006). Specifically, the risk of depressive symptoms/disorders is high either in the ear-
ly stages of the perimenopausal transition, i.e. when the estrogen levels are transiently 
high (Freeman et al., 2004; Freeman et al., 2006), or during the late stage, i.e. when the 
estrogen withdrawal is more significant (Schmidt et al., 2004; Steinberg et al., 2008). 
Additionally, recent results from the SWAN study (Study of Women’s Health Across 
the Nation) (Bromberger et al., 2011) show that the risk of suffering from an MDE is 
higher during the menopausal transition as well as in the short term (within 2 years) 
after entering the menopause, than premenopausally.
Taken together, these findings support the hypothesis of a hormonal contribu-
tion, in particular of hormone (especially estrogen) variability rather than increase or 
decrease (Freeman et al., 2006), to the psychological distress typical of this reproduc-
tive phase (Harsh et al., 2009). Other risk factors for perimenopausal depression in-
clude young age at menarche, heavy and irregular menstrual bleeding during the first 
five years of menstruation, a past history of depression (Hay et al., 1994), premenstru-
al dysphoria (Steinberg et al., 2008) and stressful life events in connection with the 
menopausal transition (Cohen et al., 2006). Reciprocally, women with a past history of 
MDD, especially those with more severe depressive symptoms, are at higher risk of an 
early decline in ovarian function and therefore of early transition to perimenopause 
when compared with women with no history of depression (Harlow et al., 2003).
With regard to the prevalence of anxiety symptoms during the menopausal tran-
sition, the data are quite inconsistent and inadequate (Bryant et al., 2012). A study 
(Seritan et al., 2010) found no difference between pre-, peri- and post- menopausal 
women participating in an assessment program for midlife women, even though peri-
menopausal women were more likely to report depressive/anxiety symptoms than the 
postmenopausal ones. In a study carried out among peri- and postmenopausal wom-
en in a clinical setting, a 48.6% prevalence rate of anxiety was found (Terauchi et al., 
2012), and 23.8% of postmenopausal women attending a gynecologic outpatient clin-
ic had a diagnosis of anxiety disorder, the most common one being GAD (15.6%) (Sa-
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hingoz et al., 2011). Moreover, the presence of anxiety/depressive symptoms was asso-
ciated with the severity of vasomotor symptoms in peri- and postmenopausal women 
(Seritan et al., 2010).
The prevalence rates of mood and anxiety symptoms and disorders through 
women’s reproductive lives are summarized in Table 2. Figure 2 displays the gender 
difference in the relative risk of MMD across the life-span. 
THL — Research nr/year 1 Mental health and  reproductive health in women 
 
 
 
 
Abbreviations: Major Depressive Disorder (MDD). 
Figure 1. Risk of depression across the (female) reproductive life span: gender 
differences (adapted from Deecher et al., 2008). 
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Suicidal behavior and menstrual cycle phase. Research focusing on the associa-
tions between suicidal behavior and reproductive life in women has produced 
quite mixed findings (Table 3), with studies reporting no relationships (Helweg-
Larsen & Hestbech, 1985; Vanezis, 1990; Mann et al., 1999), and others support-
ing the association between completed suicide and menstrual cycle phase. Howev-
er, even among the latter group, there are many inconsistencies. Indeed, Targum et 
al. (1991) and Gisselmann et al. (1996) reported that suicide occurs more frequent-
ly in the pre-ovulatory or para-menstrual phase, while McKinon and colleagues 
(1959) found an association between suicide (and accidental death) and luteal 
phase, with a peak in the mid-luteal phase. Other authors (in: Saunders & Hawton, 
2006; Dogra et al., 2007) showed a relationship with the late luteal/early follicular 
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2.2.4 Suicidal behavior through women’s reproductive  
 life
Suicidal behavior and menstrual cycle phase. Research focusing on the associations be-
tween suicidal behavior and reproductive life in women has produced quite mixed 
findings (Table 3), with studies reporting no relationships (Helweg-Larsen & Hestbe-
ch, 1985; Vanezis, 1990; Mann et al., 1999), and others supporting the association be-
tween completed suicide and menstrual cycle phase. However, even among the latter 
group, there are many inconsistencies. Indeed, Targum et al. (1991) and Gisselmann et 
al. (1996) reported that suicide occurs more frequently in the pre-ovulatory or para-
menstrual phase, while McKinon and colleagues (1959) found an association between 
suicide (and accidental death) and luteal phase, with a peak in the mid-luteal phase. 
Other authors (in: Saunders & Hawton, 2006; Dogra et al., 2007) showed a relation-
ship with the late luteal/early follicular phase (menstrual bleeding), with 15% to 100% 
of women committing suicide while menstruating. Similarly, Fourestié et al. (1986) 
and Caykoylu et al. (2004) suggested an higher suicide risk in the menstrual follicular 
phase, while a more recent histopathological study found a significant association be-
tween suicide and menstrual phase when comparing 56 women who died by suicide 
with a control group of 44 women who died due to other causes (25% vs. 4.5%) (Lee-
nars et al., 2009). Several studies also found that suicidal thoughts are more common 
when estrogen levels are low, i.e. in the premenstrual and menstrual phases (Mandell 
& Mandell, 1967; Wetzel et al., 1971; Chaturvedi et al., 1995).
Although a clear consensus does not exist in respect to attempted suicide (Hold-
ing & Minkoff, 1973; Birtchnell & Floyd, 1974; Luggin et al., 1984; Ekeberg et al., 1986; 
Gisselmann et al., 1996), it seems justified to state that an association with the men-
strual and premenstrual phases does exist. Indeed, Dalton (1959) reported a high-
er number of attempted suicides during the early menstrual and premenstrual phas-
es, and Tonks and colleagues (1968) detected a slightly higher prevalence of attempted 
suicide during the menstrual and luteal phases. Fourestié and colleagues (1986) found 
that the highest number of suicide attempts in women who did not use oral contra-
ception occurred during the first (42%) and after the fourth (12%) week of the men-
strual cycle, i.e. in low-estradiol phases. This is consistent with Baca-Garcia and co-au-
thors (1998), who found a high incidence of suicide attempts in the first (36%) and 
in the fourth (29%) week of the menstrual cycle, and a significantly higher than ex-
pected number of suicide attempts during the follicular (especially menstrual) phase 
(Baca-Garcia et al., 2000). In their replication study Baca-Garcia et al. (2003a) again 
showed that suicide attempts tend to be associated with the menses. Using the com-
bined results of their studies, the authors stated that “the probability of attempting su-
icide during the menses was 1.68 times higher than the overall probability of attempt-
ing suicide for any fertile women”.
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Furthermore, the risk of suicidal, aggressive or impulsive behavior is higher in 
women with PMS/PMDD (Endicott & Halbreich, 1988), and the rates of suicidal ide-
ation among women contacting a clinic for PMS ranged from 17% to 63% (Halbreich 
et al., 1982; Stout et al., 1986). Recent data from a national representative sample of 
American women (Pilver et al., 2013) found a gradual rise in the prevalence of suicid-
al behavior (ideation, plans and attempts) from women with no premenstrual symp-
toms, to women with moderate/severe PMS, to women with PMDD. In the same study, 
moderate/severe PMS was associated with risk of suicidal ideation (OR 1.49), and PM-
DD with an increased risk of suicidal ideation (OR 2.22), suicidal plans (OR 2.27) and 
attempts (OR 2.10). Similar results were gained from a Korean study, where women 
with PMDD had a higher risk of lifetime and 12-month suicidal ideation compared 
with women with no PMDD (similar, but non-significant trends were detected in re-
spect to suicidal plans and attempts) (Hong et al., 2012). Reciprocally, women with 
suicidal ideation are more likely to complain of premenstrual symptoms such as low 
mood, irritability and water retention (Chaturvedi et al., 1995).
Table 3. Suicidal behavior during the menstrual cycle.
Menstrual cycle phase
No relationship Pre-ovulatory or para-
menstrual phase
Late-luteal or men-
strual-follicular phase
Mid-luteal 
phase
Completed 
suicide
Helweg-Larsen & 
Hestbech, 1985
Vanezis, 1990
Mann et al., 1999
Targum et al., 1991
Gisselmann et al., 1996
Fourestié et al., 1986
Caykoylu et al., 2004
Saunders & Hawton, 
2006
Dogra et al., 2007
Leenaars et al., 2009
McKinon et al., 
1959
Attempted
suicide
Holding & Minkoff, 
1973
Birtchnell & Floyd, 
1974
Luggin et al., 1984 
Ekeberg et al., 1986
Targum et al., 1991
--- Dalton, 1959
Tonks et al., 1968
Fourestié et al., 1986
Baca-Garcia et al., 1998
Baca-Garcia et al., 2000
Baca-Garcia et al., 
2003a
---
Suicidal
ideation
--- --- Mandell & Mandell, 
1967
Wetzel et al., 1971
---
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Suicidal behavior and pregnancy. Although the rates of attempted and completed 
suicide are quite low during pregnancy and in the postpartum (Appleby, 1991; Syver-
son et al., 1991; Appleby, 1996; Marzuk et al., 1997; Catalan, 2000), high levels of sui-
cidal ideation (16.7% to 27.8%) were found among pregnant women (Newport et al., 
2007), especially in the cases of unplanned pregnancies, depressed, anxious, unmar-
ried and less-educated women (Newport et al., 2007). The authors suggested that hor-
monal changes during pregnancy may influence suicide ideation. However, it is pos-
sible that the psychosocial “supportive” milieu typical of pregnancy and postpartum 
may contribute reducing the risk of acting on suicidal thoughts (Newport et al., 2007).
Also, it seems that the pregnancy outcome itself may influence the suicidal risk 
in the postpartum period, with higher suicide rates in women who had a miscarriage 
(18.1/100 000 miscarriages) or an induced abortion (34.7/100 000 abortions) than in 
the cases of live births (5.9/100 000 live births) (Gissler et al., 1996). Similarly, Rear-
don et al. (2002) found that in the eight years after the first pregnancy event, wom-
en with induced abortion as the outcome were 62% more likely to die (from non-vio-
lent causes, suicide and accidents) than women who gave birth and had no history of 
induced abortion. This is consistent with other findings showing a (bidirectional) as-
sociation between induced abortion and suicidal behavior (Morgan et al., 1997; Mo-
ta et al., 2010).
Suicidal behavior and menopause. Ultimately, there is a general lack of informa-
tion on the relationship between completed suicide and menopause. However, Baca-
Garcia and colleagues (2010) reported that women who attempted suicide during low-
estrogen and low-progesterone states (as it is in menopause) presented more severe 
lethal intent than women who attempted suicide in other states, and Usall and col-
leagues (2009) found higher risk of suicidal ideation in perimenopause than in pre- or 
post-menopause, independently of any comorbid mood or anxiety disorder.
In conclusion, it seems that a relationship does exist between mental health and 
reproductive life in women. It is worth remembering that “reproductive life” is a com-
plex entity with a broad range of physical and psychological correlates. Indeed, repro-
ductive events are characterized by significant changes in hormone levels as well as by 
macroscopic changes in the body and in its functions. Moreover, reproductive events 
cannot be separated by their psychological and social correlates, being generally asso-
ciated with important role transitions. It is thereby understandable how reproductive 
life may have an impact on women’s mental health, or more generally, psychological 
well-being. In addition, it is clear how complex this relationship is, and how difficult 
it is to clearly disentangle the role of the biological from that of psychological factors.
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2.3 Gender differences and associated  
 factors in affective disorders and  
 suicidal behavior
There are many possible explanations for the gender difference in the epidemiology 
and phenomenology of many psychiatric conditions, including suicidal behavior. In-
deed, psychiatric disorders and suicidal behavior are complex entities, with a multifac-
torial etiology that includes cultural, social and biological aspects.
2.3.1 Cultural and social factors
Several cultural and social factors may contribute to the greater risk of depression and 
anxiety in women and to the higher risk of completed suicide in men (and attempt-
ed suicide in women).
Sociodemographic factors. Among other sociodemographic factors, marital status and 
social integration seem to play a role. Even though with mixed findings, marriage has 
been claimed as protective, or beneficial, for the mental health of men more than wom-
en (Wu & DeMaris, 1996; Kiecolt-Glaser & Newton, 2001), possibly due to women’s 
higher proneness to experiencing lower marital satisfaction, more marital distress and 
worse marital quality than men (Schumm et al., 1998). Specifically, recently it has been 
shown (Scott et al., 2010) that marriage is associated with a reduced risk of mental 
disorders in general in men as well as in women engaged in their first marriage when 
compared with never married individuals. However, when looking at the single diag-
noses separately, the reduction in the risk of MDD, dysthymia and panic disorder was 
evident only for men; on the contrary, a reduced risk for substance abuse was more 
prominent in women. Different effects of marriage in respect to gender where found 
also in an elderly population, where marriage per se (i.e., even in the presence of mari-
tal conflicts) was protective against depression in men, but not in women (Mechakra-
Tahiri et al., 2010). Moreover, the end of a relationship (due to separation, divorce 
– even in the case of a remarriage – or widowhood) seems to be associated with an in-
creased risk of any mental disorder both in men and women (when compared with 
currently married subjects), but again the associations were more evident among men 
as regards depressive disorders, and in women in respect to substance abuse (Scott et 
al., 2010). However, married women with a diagnosis of bipolar disorder were found 
to have less depressive episodes and less severe depressive scores when compared with 
unmarried bipolar women, while no difference was found between married and un-
married bipolar men (Lieberman et al., 2010).
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Cultural factors. Cultural factors may also partly explain the so-called “gender para-
dox” in suicide (Canetto & Sakinofsky, 1998). A less perceived need for help and lower 
access to the health care systems, as well as higher levels of impulsivity and aggressive-
ness in men may contribute to the higher suicide rates in men compared with wom-
en. Women more frequently choose less lethal suicidal methods such as drowning and 
poisoning (overdoses). On the other hand, men tend to choose more aggressive meth-
ods which often result in completed suicide (Rich et al., 1988; Marusic, 1999). How-
ever, the choice of suicide methods is not an exact measure of the real lethal intent, 
but it can rather be an expression of a cultural influence in the choice of the suicid-
al means, with poisoning by psychotropic drugs being a typical “feminine” method of 
suicide (Canetto & Sakinofsky, 1998). Indeed, in western countries, such as the United 
States, suicide is usually viewed as a “masculine” behavior, and therefore inappropriate 
for women, while attempted suicide is considered more “feminine” behavior (Canetto, 
2008). Additionally, masculinity, in contrast to femininity, often means strength, deci-
siveness and inexpressiveness of emotions; hence, an inability to fulfill this role, along 
with the impossibility of expressing emotions, may lead to risky behaviors (Canetto 
& Cleary, 2012). In other cultures, including China, suicide is considered an act of the 
powerless, and men who commit suicide are considered weak and effeminate (Canet-
to, 2008). In this context suicide is usually in response to interpersonal conflicts/abuse 
within the family, and is considered a socially acceptable means of revenge for the 
powerless, as women usually are within these societies. These social and cultural be-
liefs certainly do play a role in determining the typical epidemiological pattern of sui-
cidal behavior (Canetto, 2008).
Another hypothesis is that the gender difference in psychiatric disorders reflects a 
difference in the “gender roles”, which includes different life events and stressors, along 
with different coping skills, among men and women in the context of their countries 
and cultures. As a consequence of this theory, the increasing equality between men and 
women in many countries has been accompanied by a progressive reduction in the 
gender gap in depression and other disorders. Recently, it has been shown (Seedat et 
al., 2009) that the gender difference in the prevalence of MDD and substance abuse is 
smaller (i.e., there is a trend for less depressed, but more abuser women) in the young-
er than in the older generations. This phenomenon was accompanied by a progressive 
reduction in the gender role traditionality (in terms of women’s education and em-
ployment, age at marriage and use of contraception), suggesting that the closer the 
gender roles come together, the smaller the differences in the epidemiology of “gen-
der-related” phenomena, such as the prevalence of some psychiatric conditions (in-
cluding suicidal behavior).
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2.3.2 Biological factors
Along with cultural and social background, biology has to be taken into account when 
looking at psychiatric disorders and at their epidemiology. Male and female brains sig-
nificantly differ at structural, neurochemical and molecular levels. Several factors such 
as hormone-independent, genetic (Arnold et al., 2003) and environmental agents in-
tervene in determining the sexual differentiation of the brain, which starts already 
during the fetal life. Additionally, sexual hormones are known to primarily contribute 
to this process. These and other biological differences could partly explain the pattern 
of the epidemiology of many mental disorders, such as depression.
2.3.2.1 Structural brain differences
In addition to the microscopic structural differences (cell size, characteristics and 
number of axons, dendrites and spines), there are several macroscopic gender differ-
ences in the brain. The overall volume of the male brain is larger than the volume of 
the female brain (though women have greater cortical thickness than men), with the 
amygdala and cerebellum being larger in men and the hippocampus in women, and 
women having a higher percentage of gray matter relative to the total intracranial vol-
ume (Gur et al., 1999; in Cosgrove et al., 2007). Also the nucleus of the preoptic area 
in the hypothalamus is larger and contains more cells in men than in women. Other 
brain structures related to emotions differ between men and women, with the cingu-
lated and the ventrolateral prefrontal cortices being larger in women. Paus and co-
workers (2010) found that the overall brain volume, as well as the absolute volumes of 
the white and, to a lesser extent, the gray matter, are already higher in male than in fe-
male adolescents. However, the gray matter volume corrected for the total brain vol-
ume was higher in girls than in boys, and the opposite with regards to the white mat-
ter. Also, they found that the (absolute and relative) volume of white matter increases 
with age significantly more in male than in female adolescents, while relative gray mat-
ter volume decreases with age similarly in adolescent boys and girls. It has also been 
shown that the volume of the gray matter in some cerebral regions may vary during 
the menstrual cycle (declining during ovulation), and is larger in women using hor-
monal contraception (Pletzer et al., 2010). Moreover, the global cerebral blood flow 
is higher in women than in men, and an estrogen-dependent regulation has been hy-
pothesized (Cosgrove et al., 2007).
2.3.2.2 Genetic influence
Genetic factors play a role in the complex, multifactorial etiology of depression, and 
several genes and gene polymorphisms, especially those involving components of the 
monoaminergic systems (e.g., catechol-O-methyltransferase, monoamine oxidase 
A, serotonin transporter), have been suggested as potential candidates. Additionally, 
many studies have provided evidence for gender differences in the genetic susceptibil-
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ity to depression, and a genome-wide association study revealed several gene–gender 
interactions, as well as gender-specific gene associations, in relation to MDD (Aragam 
et al., 2011). It is therefore possible that, due to different gene expressions, steroid hor-
mones have different effects in female and male brain.
Specifically, the activity of the catechol-O-methyltransferase is less pronounced 
in women than in men (due to an estrogen-mediated down-regulation), and the spe-
cific polymorphisms of the catechol-O-methyltransferase gene associate with psychi-
atric disorders and poor response to antidepressants in men but not in women (Tsai 
et al., 2009). Furthermore, the association between depression and stress, as well as the 
serotonin turnover itself, vary between genders according to different polymorphisms 
of the serotonin transporter gene (Williams et al., 2003; Brummett et al., 2008; Ham-
men et al., 2010).
Several other genes seem to be involved in the gender difference of MDD (e.g., the 
protein tyrosine phosphatase receptor R gene, an androgen-regulated gene whose ex-
pression varies with menstrual cycle phase) (Shi et al., 2012). Also, a rare allelic variant 
of the gene encoding for preprogalanin (a precursor of the amino acid peptide gala-
nin) was found to be associated with more severe anxious symptoms in female, but 
not male, patients, and with more severe depressive symptoms (and less likelihood of 
remission) in female premenopausal, but not postmenopausal or male patients (Un-
schuld et al., 2010). 
Taken together, these findings, along with many other reports on a gene–gender 
interaction in relation to depression and other psychiatric disorders, contribute to ex-
plaining the gender difference in the epidemiology, onset and course of depression, 
anxiety and other psychiatric disorders.
2.3.2.3 immune systems
The importance of the immune system in depression, anxiety and several other psy-
chiatric disorders has been highlighted over the past 20 years (Maes, 2011). Specifical-
ly, depression is characterized by markers of inflammatory response (e.g., increased 
levels of interleukin-1β, interleukin 6 and tumor-necrosis factor-α). In particular, de-
pression seems to be associated with a cell-mediated immune activation, with a Th1/
Th2 balance shifted towards Th1 and increased levels of serum interleukin 2 receptor 
concentrations. These alterations are linked to the altered glucocorticoid response and 
to the tryptophan depletion typically found in depressed patients (Maes, 2011).
In general, the immune response differs by gender especially during fertile life. 
Several components of the immune systems, including B and T lymphocytes, neutro-
phils and macrophages express (nuclear and membrane) estrogen receptors. Further-
more, estrogens are known to modulate the maturation of B and T cells, high levels of 
estrogens being associated with a Th1/Th2 ratio in favor of Th2, and low estrogen lev-
els (as it is the case during the menstrual and luteal phases) with a balance shifted to-
wards Th1. Additionally, estrogens have a promoting effect on B-lymphocytes, while 
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the levels of neutrophils have been found to vary according to the menstrual cycle 
phase (Pennell et al., 2012).
This evidence supports the hypothesis of an interaction between gonadal hor-
mones and the immune system, and its possible contributive role in the gender differ-
ence in depression and other psychiatric disorders.
2.3.2.4 Neurotransmitters
According to the so-called “monoaminergic theory”, depression arises from altered 
levels of neurotransmitters, such as serotonin, noradrenalin and dopamine. Gender 
differences in the levels, synthesis and/or metabolism of these peptides, as well as in 
the localization and function of the monoaminergic, cholinergic, GABAergic and pep-
tidergic systems, may partly explain the gender difference in many psychiatric disor-
ders.
Serotonin. In general, women have higher blood serotonin and lower plasma lev-
els of 5-hydroxyindoleacetic acid than men (Ortiz et al., 1988). However, serotonin 
synthesis was found (Nishizawa et al., 1997; Sakai et al., 2006) to be much (52%) low-
er in several brain regions in healthy women than in men, even though the amount 
of serotonin stored in the brain is probably similar between genders. The gender dif-
ference in the synthesis of serotonin is more evident in the left side of the brain and it 
only involves the cortical regions (Sakai et al., 2006). Nishizawa and colleagues (1997) 
hypothesized that a higher use than usual of serotonin in response to stress is accom-
panied in women (but not in men) by reduced, or not effective enough, serotonin syn-
thesis, this in turn resulting in serotonin depletion that could explain the proneness to 
stress-triggered depression in women. Also, in the same study the authors found that 
acute tryptophan depletion led to a significantly larger reduction of serotonin synthe-
sis in women than in men. However, other studies found that the serotonin synthe-
sis was higher in several cortical regions, as well as in some regions of the limbic sys-
tem, in women with a diagnosis of MDD than in men suffering from MDD (Frey et 
al., 2010).
Regarding the serotonin receptor and transporter, the serotonin receptor 5-HT1A 
binding potential is (39%) higher in healthy women than in men (Jovanovic et al., 
2008), and it was found to decrease with age in men but not in women (Cidis Melt-
zer et al., 2001). On the contrary, men exhibit a (55%) higher serotonin transporter 
binding potential than women (Jovanovic et al., 2008), even though its density in the 
diencephalon seems to be lower in depressed (young) women compared with healthy 
controls and depressed men. Interestingly, the number of diencephalon serotonin 
transporters decreased with age in healthy women and men as well as in depressed 
men, but increased in depressed women (Staley et al., 2006).
These findings suggest that baseline serotonin activity is higher in women than 
in men, but a gender-specific (probably estrogen-mediated) modulation of the seroto-
ninergic activity in women may lead to enhanced vulnerability to depression.
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Dopamine, Noradrenalin and Gamma-Aminobutyric Acid. Dopamine activity 
and dopamine transporter levels are higher in women than in men; this probably ex-
plains, at least in part, the higher rates of alcoholism and related disorders in men than 
in women (Cosgrove et al., 2007). Cortical gamma-aminobutyric acid levels are also 
higher in women than in men, and they seem to change accordingly to the menstrual 
cycle phase (high in the follicular, low in the luteal phase in healthy women, and vice 
versa in women with PMS) (Epperson et al., 2002).
There is scant information on the gender difference in cerebral noradrenalin, in 
spite of its well-established role in depression. However, levels of noradrenalin were 
found to correlate with the severity of alexithymia in depressed men but not wom-
en (Spitzer et al., 2005). Moreover, it seems that the levels of a noradrenalin metabo-
lite, the 3-methoxy-4-hydroxyphenylglycol, vary with age to out-range (either below 
or above the physiological range) values in women but not in men, thus suggesting a 
dysregulation of the noradrenergic system that could possibly partly explain the vul-
nerability to depression in women (Halbreich & Lumley, 1993).
2.3.2.5 Hormonal influence
Many hormonal systems are known to contribute to the etiology of depression and 
other psychiatric disorders. The most widely studied ones are the thyroid hormones, 
cortisol, estrogens and progesterone and, more recently, melatonin. It is plausible that 
these hormonal systems and their brain actions exhibit a gender pattern that could ex-
plain gender differences in psychiatric disorders.
Thyroid hormones. Thyroid diseases are significantly more frequent in women 
than in men (Vanderpump et al., 1995). Impaired thyroid function is related with de-
pressive and anxiety symptoms and disorders, and thyroid hormones are considered 
to interact with neurotransmitter systems (such as the serotoninergic and dopamin-
ergic systems) known to be involved in the etiology of mood disorders (Bauer et al., 
2002; Bauer et al., 2008). Reciprocally, even though overt hypo- or hyper- thyroidism 
are rare among depressed outpatients, a proportion of them do exhibit a trend for sub-
clinically altered levels of thyroid hormones (Fava et al., 1995; Bauer et al., 2008).
In general, although the connection between the high prevalences of thyroid dis-
eases and depression and other psychiatric disorders in women is unclear, it is not pos-
sible to rule out its contributive role to women’s high vulnerability to depression.
Cortisol. Abnormal cortisol levels are associated with depression, with a propor-
tion of depressed patients exhibiting higher mean cortisol levels and no cortisol de-
crease in response to a dexamethasone suppression test both in men and women. 
However, some gender differences in cortisol secretion, levels and activity have been 
detected. The hypothalamic regions responsible for the secretion of the corticotropin-
releasing hormone present a sexual dimorphism, with men having more corticotro-
pin-releasing hormone neurons (and having a larger posterior lobe of the pituitary) 
than women. Furthermore, the cortisol response to the dexamethasone suppression/
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corticotropin-releasing hormone stimulation test at admission was found to vary ac-
cording to the future depression outcome (symptom remission or not at five weeks of 
treatment) in depressed male but not female inpatients (Binder et al., 2009). Postmen-
opausal depressed women had higher cortisol levels after a dexamethasone test than 
premenopausal depressed women (Young, 1995), suggesting a gonadal-hormone-me-
diated association. Moreover, depressed women had higher, and men lower, evening 
adrenocorticotropic hormone secretion than their age- and sex-matched healthy con-
trols (Young & Ribeiro, 2006). Lastly, women with depressive symptoms had higher 
levels of afternoon and evening salivary cortisol than women with no symptoms, while 
no difference was found between depressed and healthy men (Muhtz et al., 2009). 
These results are suggestive of a gender modulation of the hypothalamic–pituitary–ad-
renal axis function in depression.
The above-described findings may be explained by genetic polymorphisms. As an 
example, a specific polymorphism in the gene encoding for the α2 adrenoceptor is as-
sociated with abnormal cortisol responses in depressed men but not women, while it is 
the opposite in the case of the β2 adrenoceptor (Haefner et al., 2008). Another finding 
is that healthy men carrying the S variant of the serotonin transporter gene have high-
er diurnal cortisol levels, as well as lower cortisol response to morning awaking, and 
lower adrenocorticotropic hormone levels after the dexamethasone test, than those 
carrying the L variant. On the contrary, no such associations (or even opposite results) 
were found in (same age) healthy women (Wust et al., 2009; Wankerl et al., 2010).
Melatonin. Melatonin is a hormone produced primarily by the pineal gland. The 
synthesis of melatonin starts from the serotonin precursor, tryptophan, and is indi-
rectly regulated by the light/dark cycle (Arendt, 2005). Melatonin is known to be in-
volved in modulation of circadian rhythms (e.g., sleep and body temperature), as well 
as in the regulation of immune and cardiovascular functions, mood and reproductive 
biology (Srinivasan, 1997; Srinivasan et al., 2005). Melatonin levels and their rhyth-
micity seem to be altered in many psychiatric disorders, the seasonal affective disor-
der (which is 3.5 times more prevalent in women) being characterized by a delayed 
morning decrease of melatonin levels (Pacchierotti et al., 2001). However, studies are 
not consistent with respect to reporting a trend for higher (Rubin et al., 1992), low-
er (Brown et al., 1985; Khaleghipour et al., 2012) or the same (Carvalho et al., 2006) 
night-time melatonin levels in depressed subjects compared with healthy controls. In-
terestingly, Rubin and colleagues (1992) found a trend for higher night-time mela-
tonin levels in depressed patients than in healthy controls only among premenopausal 
women, but not among postmenopausal women or men. Also, the offset of melatonin 
secretion seems to be phase-advanced in women suffering from PMS, with a conse-
quent shorter duration and an overall lower melatonin secretion than in women with 
no PMS (Parry et al., 1990; Parry et al., 1997).
Gonadal hormones. The activity of many of the above-mentioned hormones and 
neurotransmitters varies according to menstrual cycle and reproductive phases, and is 
known to be modulated by gonadal steroids. The serotoninergic neurons in the mid-
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brain, as well as noradrenergic and cholinergic neurons in the basal forebrain, are all 
targets of the estrogens. Estrogens induce a rise in serotonin (and noradrenalin) lev-
els due to the reduced expression of monoamine oxidases and the enhanced activity of 
tryptophan hydroxylase, the rate-limiting enzyme of the synthesis of serotonin. Estro-
gens also modulate the expression and activity of the serotonin reuptake transporters 
and influence the distribution and regulation of serotoninergic receptors (Rubinow et 
al., 1998; Genazzani et al., 2007; Gasbarri et al., 2012). Similarly, progesterone has neu-
ropsychological and neuroprotective functions, and is involved in the control of opioi-
dergic, serotoninergic and cholinergic systems (Pluchino et al., 2009).
Jovanovic et al. (2009) found no differences in the binding potentials of seroto-
nin receptor or serotonin transporter between the follicular and luteal phase of healthy 
women, while Wihlbäck et al. (2004) reported that the number and binding affinity 
of the platelet serotonin transporters and receptors varies according to the menstru-
al cycle phase and is correlated with the concentrations of estrogen and progesterone. 
Baca-Garcia et al. (2003b) studied the interaction between estrogens and the gene of 
the serotonin transporter in determining the risk of attempted suicide. Women with 
the S allelic variant of the serotonin transporter gene (with lower serotoninergic activ-
ity) are per se at higher risk of suicide, a diminished serotoninergic activity being as-
sociated with high suicidal risk (Mann, 1998). However, Baca-Garcia and colleagues 
(2003b) found that women with the L gene variant are more sensitive to the reduction 
in estrogen levels (which leads to a consequently diminished serotoninergic activity), 
and thus are more vulnerable to suicide during the low estrogen phases (i.e., premen-
strually and in menopause).
Melatonin production is also partly regulated by sex hormones. Receptors for 
gonadal hormones have been found in the human pineal gland (Luboshitzky et al., 
1997), and receptors for melatonin in the human ovaries (Niles et al., 1999). Moreover, 
even though the level of melatonin seems not to vary with the menstrual cycle phase, it 
has been found to be higher when estrogen levels are lower (e.g., in the case of amen-
orrhea) (Brzezinski et al., 1988), as well as in women using oral contraception (Kosto-
glou-Athanassiou et al., 1998).
These and several other findings provide evidence for the gender-dependent role 
of gonadal steroids as factors contributing to the pathogenesis of psychiatric disorders.
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2.4 Endogenous and exogenous gonadal  
 hormones
2.4.1 Physiology of the reproductive cycle
During fetal life levels of luteinizing hormone (LH) and follicle stimulating hormone 
(FSH) are high, almost equal to the postmenopausal levels. At birth they stay high for 
a few months and years, respectively; they subsequently decrease and remain low and 
stable until puberty.
Puberty. Puberty is a sequence of events leading to physical and psychological 
changes resulting in adult physical characteristics and the capacity to reproduce. In 
girls the first visible change of puberty is usually the breast development, followed by 
the growth of pubic and axilla hair. The first menstrual period generally occurs be-
tween 12 and 13 years.
It is not completely clear which mechanisms are involved in the initiation of pu-
berty. Central influences may inhibit release of the gonadotropin-releasing hormone 
during childhood, and stimulate its release to induce puberty in early adolescence. 
The hypothalamus secretes gonadotropin-releasing hormone, which regulates the re-
lease of the gonadotropins LH and FSH from the anterior pituitary gland. These hor-
mones induce ovulation and the consequent secretion of the sex hormones estradiol 
and progesterone from the ovaries, which in turn stimulate the target organs of the re-
productive system.
Menstrual Cycle. The average duration of the menstrual cycle is 28 days; it begins 
and ends with the first day of menses. The menstrual cycle consists of follicular (pre-
ovulatory), ovulatory, and luteal (post-ovulatory) phases (Figure 3).
Follicular phase. This phase is the less constant in its duration. In the early folli-
cular phase the levels of LH and FSH in the anterior pituitary are low, as it is the pro-
duction of estrogen and progesterone. FSH secretion increases slightly; also, circulat-
ing LH levels rise slowly, starting from one to two days following the increase in FSH. 
The production of estradiol from the recruited ovarian follicles increases rapidly; this 
leads to increased synthesis, but reduced secretion, of LH and FSH. During the second 
half of the follicular phase (late follicular phase) FSH levels decrease, while LH levels 
are affected less. This is partly because estradiol inhibits FSH more than LH secretion. 
In addition, the hormone inhibin is produced by the developing follicles. This hor-
mone is able to inhibit FSH but not LH secretion. Levels of estrogen, particularly es-
tradiol, increase exponentially.
Ovulatory phase. It is characterized by the occurrence of ovulation. Estradiol lev-
els usually peak at the beginning of this phase. Progesterone levels also increase. The 
LH surge (i.e., a massive release of stored LH) occurs, while FSH levels increase at a 
smaller amount. The LH surge is also stimulated by high levels of estradiol (posi-
tive feedback), by gonadotropin-releasing hormone and progesterone. During the LH 
surge, estradiol levels decrease, while progesterone levels continue to increase.
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Luteal phase. The follicle is transformed into a corpus luteum. This phase is the 
most constant in its duration, usually 14 days, after which the corpus luteum degen-
erates. Increasing quantities of progesterone are released primarily by the corpus lute-
um. Levels of circulating estradiol, progesterone, and inhibin are high during most of 
the luteal phase; consequently, LH and FSH levels decrease. Estradiol and progesterone 
levels decrease late in this phase.
Menopause. The permanent end of menstrual periods, and of fertility, is called 
menopause. As women age, the production of estrogens and progesterone from the 
ovaries gradually decreases; thereby menstrual periods and ovulation occur less often. 
Eventually, when the complete depletion of active follicles occurs, the menstrual pe-
riods and ovulation cease permanently. This leads to the absence of estrogen negative 
feedback: consequently, FSH and LH levels rise significantly, reaching concentrations 
that are 13 times and 3 times higher, respectively, than normal early follicular phase 
concentrations.
The term “perimenopause” identifies a specific transitional period which occurs 
during the years before and the year after the last menstrual period. The perimeno-
pause is characterized by marked fluctuations in the levels of estrogen and progester-
one. In perimenopause there is also a marked elevation of early follicular-phase FSH 
levels, not always followed by a rise in LH levels (Sherman et al., 1976). These fluctua-
tions probably cause the menopausal symptoms experienced by many women in their 
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Menopause. The permanent end of menstrual periods, and of fertility, is called 
menopause. As women age, the production of estrogens and progesterone from the 
ovaries gradually decreases; thereby menstrual periods and ovulation occur less 
often. Eventually, when the complete depletion of active follicles occurs, the 
menstrual periods and ovulation cease permanently. This leads to the absence of 
estrogen negative feedback: consequently, FSH and LH levels rise significantly, 
reaching concentrations that are 13 times and 3 times higher, respectively, than 
normal early follicular phase concentrations. 
The term “perimenopause” identifies a specific transitional period which 
occurs during the years before and the year after the last menstrual period. The 
perimenopause is characterized by marked fluctuations in the levels of estrogen 
and progesterone. In perimenopause there is also a marked elevation of early 
follicular-phase FSH levels, not always followed by a rise in LH levels (Sherman 
et al., 1976). These fluctuations probably cause the menopausal symptoms 
experienced by many women in their 40s and 50s (flushes, sweating, palpitations, 
tachycardia). 
The entire transition takes a period of 10 to 15 years (Morrison et al., 2006). 
Figure 3. Gonadotropine and gonadal hormone cycles
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40s and 50s (flushes, sweating, palpitations, tachycardia). The entire transition takes a 
period of 10 to 15 years (Morrison et al., 2006).
2.4.2 Estrogens, progesterone and the central nervous  
 system
The effects of gonadal hormones (i.e., estrogen, progesterone and testosterone) on the 
central nervous system are evident already during fetal life. Indeed, gonadal steroids 
are partly responsible for the sexual brain differentiation and, after the development 
of gonads, they drive specific organizational and developmental changes in the brain. 
The testosterone produced by the male gonads is converted into estradiol: in this way 
it is able to bind the estrogen receptors in the developing brain, leading to masculini-
sation and defeminisation of the male brain. Conversely, in the female fetus, the ma-
ternal estrogens are bound by the α-fetoprotein, thus preventing masculinisation –de-
feminisation of the female brain (Lenz et al., 2010). Thus, sexual differentiation of the 
brain starts in the second semester of pregnancy and continues until adulthood (Swaab, 
2007). In the adult brain estrogen and progesterone receptors are widely expressed. Es-
trogen receptors are present not only in the hypothalamus (where they mostly control 
the reproductive function), but also in the hippocampus (known to be sexually differ-
entiated), amygdala, locus coeruleus, cerebellum, as well as in the pituitary, basal fore-
brain, cerebral cortex and glial cells (Genazzani et al., 2007). Moreover, cholinergic, no-
radrenergic, serotoninergic and dopaminergic neurons also respond to estrogens and 
progesterone. It is of note that the effects of gonadal hormones change depending on 
the type of receptor they bind to. Indeed, binding to the nuclear receptors α and ß leads 
to a delayed and prolonged “genomic” effect. Target genes include those encoding for 
neurotransmitters, enzymes and receptors (possibly with differences between men and 
women). Conversely, binding to membrane receptors leads to rapid, “non-genomic” ef-
fects which include the activation of cascades of signals (involving a variety of second 
messengers) (Rubinow et al., 1998; Genazzani et al., 2007) (Figure 4).
In this way, a high number and variety of cells in the brain are estrogen-respon-
sive. However, it is worth remembering that each brain region, or even each cell in 
the same brain region, may express different estrogen receptors leading to different 
responses; moreover, the same receptor may activate different signals and pathways. 
Furthermore, since the non-genomic effects require the actions of second messengers, 
and since the second messengers may differ from tissue to tissue, it is possible that the 
same hormone, even binding to the same type of receptor, leads to different effects de-
pending on the target tissue (e.g., to stimulation or rather inhibition of the same neu-
rotransmitter). That is, the final response to a gonadal steroid is extremely complex 
and depends on “the context”, i.e. type of receptor and presence and type of co-regu-
lators (Rubinow, 2005).
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2.4.3 Hormonal contraception and mental health
The widespread use of hormonal contraception and replacement therapy has brought 
the question of possible effects of exogenous estrogens and progestins in women.
A great amount of research has been focused on side effects and beneficial effects 
of hormonal contraceptives, with the general conclusion that oral contraceptive (OC) 
use is associated with several health benefits, such as lower risks of endometriosis, and 
of endometrial and ovarian carcinoma (Maia & Casoy, 2008; Braem et al., 2010). How-
ever, little is known about the effects of hormonal birth control on mental health. It is 
likely that contraception per se has a beneficial psychological effect as women do not 
need to be afraid of an unplanned pregnancy. On the other hand, due to their several 
brain effects, the contraceptive steroids as well as their downstream endocrine effects 
may have consequences on mood and anxiety. In this respect, the findings reported 
in the literature are contradictory and inconsistent. In an earlier study by Herzberg et 
al. (1971), it was reported that mean depression scores decreased in women continu-
ing the use of an intrauterine device (IUD) or an OC, while they increased in women 
stopping or changing OCs. More recent studies have shown no significant association 
between OC use and depression (Duke et al., 2007; O’Connell et al., 2007). Rapkin et 
al. (2006) found no relationship between OC-induced reduction in the concentrations 
of circulating neuroactive steroids and mood or anxiety symptoms in healthy wom-
en. Nevertheless, depression is often mentioned as a possible side-effect of OCs as well 
as of hormonal contraceptive implants or injections, and women continue to report 
depression and other mood changes as common reasons for discontinuation of OCs 
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(Oinonen & Mazmanian, 2002). It has been suggested that mood and affective chang-
es such as OC side effects may occur in a subgroup of vulnerable women (Oinonen & 
Mazmanian, 2002; Rapkin et al., 2006). In particular, one hypothesis claims that wom-
en who experience side effects of OCs are more sensitive to hormonal changes (Bird 
& Oinonen, 2011) since they have been found to be at higher risk of postpartum de-
pression (Bloch et al., 2005) and distress at menopausal transition (Stewart & Boydell, 
1993). Moreover, women who develop mood symptoms as a side effect of OCs are 
more likely to suffer from eating disorder symptoms (Bird & Oinonen, 2011) and to 
be characterized by specific personality traits, such as somatic anxiety and stress sus-
ceptibility (Borgström et al., 2008). Lastly, women who suffered from affective chang-
es while taking combined oral contraceptives (COCs) are at risk of further depressive 
symptoms during a following COC cycle (Gingnell et al., 2012).
Information concerning the possible side effects of the levonorgestrel-releasing 
intrauterine system (LNG-IUS) on mental health is even scantier. Since its introduc-
tion in the 1990s, it has been increasingly used in contraception as well as in the treat-
ment of heavy menstrual bleeding worldwide. Studies concerning acceptability and 
the reasons for and rates of discontinuation indicate bleeding problems, amenorrhea 
and hormonal adverse effects as possible consequences of use of the LNG-IUS (Rön-
nerdag & Odlind, 1999; Inki, 2007). The majority of the studies report that LNG-IUS 
users experience a significant improvement in their quality of life and psychological 
well-being (Skrzypulec & Drosdzol, 2008), with satisfaction rates ranging from 50% 
(Daud et al., 2008; Ewies, 2009) to 90% (Römer & Linsberger, 2009), both in the case 
of consecutive use of the LNG-IUS either for contraception or for the treatment of 
heavy menstrual bleeding (Römer & Linsberger, 2009; Heikinheimo et al., 2010). In 
a Finnish survey on premature removal of the LNG-IUS, bleeding disorders were the 
main reason for discontinuation (Backman et al., 2000). However, mild and rare hor-
monal side effects have been reported, such as nausea, breast tenderness, headache, 
skin problems, mood changes and nervousness (Luukkainen, 1991; Luukkainen et al., 
1990; Luukkainen et al., 2001), and in a study carried out in India to analyze the use of 
the LNG-IUS as a treatment for menorrhagia, 8% of the users reported mood chang-
es and 3% reported depression as a side effect of the LNG-IUS (Kriplani et al., 2007). 
However, to the best of our knowledge, no study has specifically been focused on the 
effects of the LNG-IUS on mental health.
2.4.4 Hormone therapy in peri- and postmenopausal  
 women
Even though the majority of women do not develop depressive symptoms or disor-
ders in connection with the menopausal transition, a subgroup seems to be vulnerable 
to mood impairment during the perimenopause, with 15% to 50% of perimenopau-
sal women experiencing depressive symptoms (Clayton et al., 2008; Timur & Sahin, 
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2010). As already said, the risk of perimenopausal depression seems to be higher dur-
ing the late stage of the menopausal transition, i.e. when the estrogen withdrawal is 
more significant (Schmidt et al., 2004; Steinberg et al., 2008). Therefore, it would be 
intuitive to hypothesize that, if the estrogen withdrawal is a contributing factor to pe-
rimenopausal depression in vulnerable women, estrogen therapy (ET) and/or com-
bined estrogen plus progestogen therapy (EPT) would be of help in preventing or 
attenuating the correlated symptomatology. Indeed, ET has been suggested as an an-
tidepressant agent or as an augmentation strategy for peri- and postmenopausal de-
pression. Some studies have shown a beneficial effect of ET on psychological well-be-
ing and quality of life (Wiklund et al., 1993; Karlberg et al., 1995), as well as on the 
treatment of depressive disorders (Soares et al., 2001) in perimenopausal and post-
menopausal women. The latter study showed transdermal estradiol to be effective in 
treating MDD, minor depressive disorder and dysthymic disorder in perimenopausal 
women independently of its effects on climacteric symptoms. This was consistent with 
a similar report of reduced depressive symptoms in perimenopausal women with a di-
agnosis of major or minor depressive disorder irrespectively of climacteric symptoms 
such as hot flushes (Schmidt et al., 2000). However, other studies have failed to find 
any mood improvement with estrogen-only therapy in depressed peri- and postmen-
opausal women (Coope, 1981; Morrison et al., 2004).
As far as it concerns combined EPT, in a randomized controlled trial Hlatky 
and colleagues (2002) found a more notable improvement of depressive symptoms 
among women assigned to EPT than to placebo, and postmenopausal depressed EPT 
or ET users seem to have a better response to selective serotonin reuptake inhibitors 
than women using no hormone therapy (HT) (Zanardi et al., 2007). However, there 
is some inconsistency on this issue. Indeed, the effects of progestogens on mood are 
quite questionable, and it seems that they may counteract the positive estrogenic ef-
fects and even induce depressive mood swings (Sherwin, 1999). In the above-men-
tioned study by Hlatky et al. (2002), women complaining of postmenopausal symp-
toms (i.e., flushing) had an amelioration of their mental health and depressive scores 
with EPT; on the contrary, EPT use was associated with poorer quality of life in terms 
of physical functioning and energy score. On this respect, it must be kept in mind that 
unopposed estrogen cannot be administered to women with an intact uterus, due to 
an increased risk of endometrial hyperplasia (Writing Group for the PEPI Trial, 1996). 
Therefore, a combination of estrogen plus progestogens is required in non-hysterect-
omized women.
In conclusion, female gonadal hormones affect multiple sites in the central nerv-
ous system. Also, several unquestionable benefits for women’s health come from the 
use of exogenous hormones in terms of both contraception and replacement therapy. 
Even though the nature of these benefits is partly intuitive – as in the case of benefi-
cial correlates of not having to be worried about unwanted pregnancies –  there is still 
quite a debate on the effects that exogenous hormones, in different forms and combi-
nations, may have on mental health per se.
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3 Aims of the study
The aim of this study was to investigate the associations between mental health and 
psychological well-being of women in relation to their reproductive features. The 
main research questions and hypotheses were the following:
I Is a history of miscarriage related to further impairment of mood or psychological 
well-being? If so, is this impairment related to an increasing number of miscarriages? 
The main hypothesis was that there is a relationship between pregnancy outcome 
and women’s mental health or psychological well-being. Specifically, having had 
one or more miscarriages is associated with depressiveness, suicidal ideation and 
other psychiatric symptoms. Also, it was hypothesized that the higher the number 
of miscarriages, the worse the psychological status even in the long-term (Study 
I).
II Does hormonal contraception have any influence on mental health or psychological 
well-being? Do different hormonal compounds differently influence mental health? 
Is the duration of use of hormonal contraception related to mental health? 
The main hypothesis was that use of hormonal contraception (and its duration) 
is not associated with a worsening of women’s psychological status or with an in-
creased risk of psychiatric diagnoses. Different psychological effects are expect-
ed depending on the type of hormonal contraceptive (OC vs. LNG-IUS) and its 
composition (second vs. third generation OCs) (Studies II and III).
III Does hormone therapy in perimenopausal and postmenopausal women have any in-
fluence on mental health or psychological well-being? Do the relationships, if any, 
differ accordingly to different hormonal compounds? 
The main hypothesis was that use of hormone therapy (either estrogen-only or 
combined estrogen plus progestogen) is not associated with a worsening of wom-
en’s mental health; rather, it may positively affect mood and psychological well-
being. Different patterns are expected depending on the composition and route 
of administration. Better mood effects are expected in the case of estrogen-only 
than in the case of combined therapy (Study IV).
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4 Subjects and methods
4.1 Materials
The data analyzed in this work were gathered from two Finnish population-based 
studies, namely the Health 2000 and the FINRISK Surveys 1997, 2002 and 2007. Data 
from the four surveys were differently combined, according to the aim of each study. 
Data sources for each study are summarized in Table 4.
4.1.1 Health 2000
Health 2000 was a cross-sectional, nationwide, population-based survey. It was car-
ried out in Finland in 2000 to 2001 (www.terveys2000.fi) through a stratified and clus-
tered sampling procedure. In this way it was possible to obtain a representative sample 
(n=8028; final sample n=6986; males=3126, females=3860) of the general population 
aged 30 years and older (Heistaro, 2008). Data were collected via a home interview and 
a clinical health examination. A total of four self-administered questionnaires were 
also given to be filled and returned. One of the self-administered questionnaires in-
cluded a modified version (Raitasalo, 1977; in http://www.terveys2000.fi/doc/meth-
odologyrep.pdf) for the Finnish population of the 21-item Beck Depression Invento-
ry (BDI-21) and the General Health Questionnaire-12 (GHQ-12). Mental health in 
the previous 12 months was assessed during the health examination via the Compos-
ite International Diagnostic Interview (CIDI), a structured mental health interview 
(Wittchen et al., 1998) (Figure 5).
A separate study was carried out on a random sample of young adults aged 18 to 
29 years (n=1894). For these, data collection consisted of a home interview and two 
self-reported questionnaires (including the GHQ-12 questionnaire).
The survey was approved by the Ethics Committee of the National Public Health 
Institute (1999) and by the Ethics Committee for Research in Epidemiology and Pub-
lic Health at the Hospital District of Helsinki and Uusimaa (2000). All participants 
gave written informed consent.
Table 4. Surveys used in Studies I, II, III and IV.
Health 2000 FINRISK 1997 FINRISK 2002 FINRISK 2007
Study I X X
Study II X
Study III X X X
Study IV X X X X
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Abbreviations: Beck Depression Inventory-21 items (BDI-21), Composite International Diagnostic Interview (CIDI), 
General Health Questionnaire-12 items (GHQ-12). 
4.1.2 National FiNRiSK Survey
The National FINRISK Study Survey is a cross-sectional, population-based health sur-
vey carried out in Finland every five years since 1972 (www.ktl.fi/finriski). The par-
ticipants were selected through random sampling of the population from the Finnish 
Population Information System; a gender-, area-, and 10-year age group- stratifica-
tion was applied.
The FINRISK-97 study covered five geographical areas of Finland (Helsinki re-
gion, south-western Finland, North Karelia, the region of Kuopio and the province of 
Oulu). Its target population was a random sample of people aged 25 to 64 years (n=10 
000); additionally, a smaller sample (n=750) of persons aged 65 to 74 years was includ-
ed from two areas. Data for the FINRISK 2002 and 2007 were collected from the cities 
of Helsinki and Vantaa, the areas of Turku and Loimaa, and the provinces of North Sa-
vo, North Karelia, Oulu and Lapland. Data were gathered from a population aged 25 to 
Figure 5. Health 2000: design of the study.
Initial sample
n=8028
(M=3637; F=4391)
Home visit interview
(assessing reproductive health)
n=6986 (F=3860)
Questionnaire 1
(including BDI-21 & GHQ-12)
n=6460 (F=3577)
Health examination
(ClDl)
n=6354 (F=3480)
Questionnaire 2
(infection questionnaire)
n=6734
Questionnaire 3
(complementary questionnarie)
n=6269
Questionnaire 4
(dietary questionnaire)
n=5998
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64 years in FINRISK 2002, and 25 to 74 years in FINRISK 2007. In FINRISK 2002, ad-
ditional data for people aged 65 to 74 years were also available from the cities of Hel-
sinki and Vantaa and the province of Lapland (Figure 6).
The survey consisted of a self-administered questionnaire and a health examina-
tion. Additionally, women participating in FINRISK 2002 were asked to complete an 
additional questionnaire inquiring in more detail into their reproductive health.
The FINRISK survey complied with the ethical rules of the National Public Health 
Institute and the Declaration of Helsinki. Ethics approval was received from the coor-
dinating Ethics Committee of the Helsinki University Hospital District.
4.2 Methods
4.2.1 Variables of interest: reproductive health
4.2.1.1 Health 2000
Data on reproductive health features were collected systematically during the non-
structured, lay-administered interviews. The questions included information on men-
strual features, pregnancies, infertility, past and current use of contraception and HT, 
and duration of its use.
Bleeding pattern and current use of hormonal contraceptives were investigated in 
the 30- to 54-year-old group. The length of time of hormonal birth control use was al-
so specified, along with the current brand of OC. The current use of hormonal contra-
ception and its duration, as well as the current brand of OC, were also assessed among 
young women (aged 18 to 29 years).
History of hysterectomy was assessed by asking if the woman had had a hyster-
ectomy and whether the uterus and both ovaries, or the uterus and one ovary, or on-
ly the uterus was removed.
Figure 6. FINRISK Surveys 1997, 2002 and 2007: design of the study.
General population
age 25–74 years 
1987
n=8446 
2002
n=9580 
2007
n=7993 
Men
n=4253 
Women
n=4193 
Men
n=4482 
Women
n=5098 
Men
n=3740 
Women
n=4253 
25–54 years
n=2773 
25–54 years
n=3665 
25–54 years
n=2448 
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Women’s reproductive status was classified as postmenopausal if time from the 
last period was 12 or more months; perimenopausal, if it was between 6 and 12 months 
or if the woman was using HT (and the periods have not ended before starting HT); 
and premenopausal, if the time since last period was less than six months.
4.2.1.2 National FiNRiSK Survey
The questions concerning reproductive health included information on menstrual cy-
cle, pregnancies, infertility, past and current use of contraception and HT, and dura-
tion of its use. The questions were similar to those used in the Health 2000 study.
History of hysterectomy was assessed via the question “Have you undergone a 
hysterectomy?”, with possible answers “no”; “yes, removal of uterus and ovaries”; and 
“yes, removal of uterus and one ovary at most” (1997 and 2007). With regard to FIN-
RISK 2002, the information was extrapolated from the question “If your menstruation 
has ended, did it end …”, with possible answers including “because of hysterectomy (at 
least one remaining ovary)” and “because the uterus and both ovaries were removed”.
Premenopausal women were identified via the questions “Do you still menstru-
ate?” with possible answers “yes, regularly”, “yes, irregularly” and “no, my last period 
was … years ago” (FINRISK 1997 and 2007), and “If your menstruation has ended, did 
it end…?”, with possible answers including “my menstruation has not ended” (FIN-
RISK 2002). Thus, a clear distinction between perimenopausal and postmenopausal 
women was not available.
The questions used to assess women’s reproductive features in the Health 2000 
and FINRISK Surveys are reported in Table 5.
Table 5. Questions used to assess reproductive health in Health 2000, FINRISK 1997, 2002 
and 2007.
Health 2000 FINRISK 1997 FINRISK 2002 FINRISK 2007
Age at menarche How old were you 
when your periods 
started?
--- How old were you 
when you started men-
struating?
---
Menstrual cycle 
regularity
Do you have periods 
nowadays ->
• regularly
• irregularly
• none
Do you still 
menstruate? ->
• yes, regularly
• yes, irregularly
• no
Have you ever had 
menstrual irregularity? 
Do you at the moment 
experience the need to 
find help to solve or al-
leviate your menstrual 
irregularity?
Do you still 
menstruate? ->
• yes, regularly
• yes, irregularly
• no
Duration of 
menstrual cycle
--- How long usually is/
was your menstrual cy-
cle (the time from the 
first menstruation day 
to next period's 
menstruation day)?
How long does it/did it 
take between the be-
ginning of your men-
struation to the be-
ginning of your next 
menstruation?
How long does/did it 
take between the 
beginning of your 
menstruation to the be-
ginning of your next 
menstruation?
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Health 2000 FINRISK 1997 FINRISK 2002 FINRISK 2007
Duration of menstrual 
bleeding
--- How many days do/
did you normally men-
struate?
How many days do you 
usually menstruate/
used to menstruate?
How many days do/
did you usually men-
struate?
Age at menopause When was your last 
period?
Do you still menstru-
ate? ->
• yes, regularly
• yes, irregularly
• no, my last period 
   was __ years ago
If your menstrua-
tion has ended, did it 
end: ->
• naturally to the men-
opause (year)
• because of hysterec-
tomy (at least one re-
maining ovary) (year)
• because the uterus 
and both ovaries were 
removed (year)
• because of radio-
therapy or other rea-
son (year)
Do you still menstru-
ate? ->
• yes, regularly
• yes, irregularly
• no, my last period 
   was __ years ago
Cause of menopause Did your periods 
end: ->
• naturally with the 
   menopause
• after an operation or 
   radiotherapy 
• for some other reason 
   (e.g. because of  
   hormone medi- 
   cation)
--- If your menstrua-
tion has ended, did it 
end: ->
• naturally to the 
   menopause 
• because of hyster-
   ectomy (at least one 
   remaining ovary) 
• because the uterus 
   and both ovaries 
   were removed 
• because of radio-
   therapy or other 
   reason
---
Number of pregnancies How many pregnancies 
have you had?
--- How many times have 
you been pregnant?
---
Number of (live) births How many children 
have you delivered? 
How many were born 
alive?
How many children 
have you born?
How many births have 
you had?
Have you given birth to 
a child/children? ->
• no
• yes (year)
Number of living 
children
How many living chil-
dren do you have at 
the moment, including 
adopted children, chil-
dren whose foster par-
ent you are and other 
“non biological chil-
dren“?
--- How many living chil-
dren do you have (in-
clude adopted and fos-
ter children and also 
other “non-biological” 
children)?
How many children do 
you have (including 
adopted children, fos-
ter children and other 
“non-biological” chil-
dren)?
Miscarriages How many miscarriages 
have you had?
--- Have you had miscar-
riages? How many?
---
Abortions How many abortions 
have you had?
--- Have you had abor-
tions? How many?
---
Infertility Have you had such time 
periods, when you have 
tried to get a child, but 
have not succeeded or 
to succeed has taken 
over 12 months?
--- Was there ever a time 
period when you tried 
to become pregnant 
but pregnancy did not 
begin or it has taken 
over 12 months?
Have you ever had 
trouble becoming preg-
nant and having chil-
dren?
Treatment for infertility Have you been in ex-
aminations because of 
childlessness/infertility 
or received treat-ment 
for it?
Have you had hormone 
therapy to treat child-
lessness?
Have you ever been ex-
amined or been treated 
for infertility?
If you have had trouble 
becoming pregnant and 
having children, have 
you consulted a doctor?
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Health 2000 FINRISK 1997 FINRISK 2002 FINRISK 2007
OC use Do you at the mo-
ment take contracep-
tive pills?
Have you used contra-
ceptive pills earlier?
What is the name of 
the preparation you are 
using now?
Are you presently on 
the contraceptive pill? 
(name of the product)
Do you at present use 
contraceptive pills?
Have you previous-
ly used contraceptive 
pills?
Have you used or do 
you at present use con-
traceptive pills?
Duration of OC use During how many years 
altogether have you 
been taking contracep-
tive pills?
Are you presently 
on the contraceptive 
pill?->
• yes, I have used the 
   pill for __ years
• no, but I have earlier 
   used it for __ years 
• I have never used it
How many years have 
you altogether used 
(now or earlier) contra-
ceptive pills?
Have you used or do 
you at present use con-
traceptive pills? ->
• yes, I do at present 
   and I have used them 
   for __ years
• no, but I have pre-
   viously used them for 
   __years
• no, I have never used 
   them
LNG-IUS use For birth-control, are 
you at the moment us-
ing a hormonal intrau-
terine device (IUD)?
Have you some time 
earlier used a hormo-
nal IUD?
Do you presently use a 
hormonal IUD?
Do you at present use 
as contraception a hor-
monal IUD?
Have you earlier used 
hormonal IUD for con-
traception?
Have you used or do 
you at present use a 
hormonal IUD for con-
traception?
Duration of 
LNG-IUS use
For how many years al-
together have you been 
using a hormonal IUD? 
Do you presently use a 
hormonal IUD? ->
• yes, I have used it for 
   __ years
• no, but I have earlier 
   used it for __ years 
• I have never used it
How many years have 
you altogether (now 
or earlier) used hormo-
nal IUD?
Have you used or do 
you at present use a 
hormonal IUD for con-
traception? ->
• yes, I do at present 
   and I have used it for 
   __ years
• no, but I have pre-
   viously used it for 
   __ years
• no, I have never 
   used it
HT use Have you, because of 
the menopause or of 
hormone deficiency af-
ter the menopause, 
used hormone replace-
ment therapy as tab-
lets, gel or sticking 
plaster during the past 
month? 
Have you earlier used 
hormone replacement 
therapy because of the 
menopause or deficien-
cy of hormones after 
the menopause?
What is the name of 
the preparation you are 
using now?
Have you used hor-
mone replacement 
therapy as tablets, gel 
or patches during the 
past month? 
Have you used hor-
mone replacement 
therapy for menopause 
or menstruation trouble 
for the last 6 months? 
Have you earlier used 
hormone replacement 
therapy for meno-
pause or menstruation 
trouble?
Have you used hor-
mone replacement 
therapy in the form of 
tablets, gel or patches 
for the last 6 months?
(name of the product)
Duration of HT use For how many years 
have you been using 
hormone replacement 
therapy?
How long have you 
used hormone replace-
ment therapy?
For how many years 
have you used hormone 
replacement therapy?
How long have you 
used hormone replace-
ment therapy?
Abbreviations: Hormone Therapy (HT), Intrauterine Device (IUD), Levonorgestrel Intrauterine System (LNG-IUS), Oral Contraceptive 
(OC).
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4.2.2 outcome variables: mental health
Mental health was assessed via structured (GHQ-12, BDI-13, BDI-21) and non-struc-
tured self-administered questionnaires and via a lay-administered, structured inter-
view (CIDI). Different questionnaires and interviews were used in the Health 2000 
and FINRISK Surveys (Figures 7 and 8).
4.2.2.1 Beck depression inventory (Bdi)
The presence and severity of depressive symptoms in the previous 2 weeks were as-
sessed via a modified version of the 21-item (Raitasalo, 1977) (Health 2000, FINRISK 
1997) and 13-item (Raitasalo, 2007) (FINRISK 2007) BDI, a reliable and commonly 
used (Beck et al., 1988) self-reported inventory validated by Beck et al. (1961) to as-
sess depression by inquiring specifically into depressive, cognitive and somatic symp-
toms. The 21-item BDI score ranges from 0 to 63, with scores of 10–16 indicating mild, 
17–29 moderate and 30–63 severe depressive symptoms. The BDI short form, Finn-
ish version, includes 13 out of the 21 original items (sadness, future hopelessness, past 
failure, dissatisfaction, self-disappointment, uselessness, suicidal ideation, lost interest 
in people, indecisiveness, feeling of looking ugly, impaired working capability, tired-
ness, and lost appetite). Its total score ranges from 0 to 39, with scores of 5–7 indicat-
ing mild, 8–15 moderate and 16–39 severe depression. BDI total scores were consid-
ered only for the cases with at least 16 (BDI-21) and 10 (BDI-13) valid answers (as in 
Raitasalo, 2007). In the case of missing values, the adjusted total score was calculated 
with the following algorhythms (Raitasalo, 2007):
•	 BDI-21: (score for questions answered/number of questions answered) x 21;
•	 BDI-13: (score for questions answered/number of questions answered) x 13.
In addition, each BDI-item score was calculated for all the participants with a val-
id answer for that item.
No BDI evaluation was available in FINRISK 2002.
4.2.2.2 General Health Questionnaire (GHQ)
Psychological well-being was assessed in the Health 2000 survey via the 12-item GHQ, 
a broadly used questionnaire introduced by Goldberg (1972) to evaluate the com-
mon mental state, with particular attention to the areas of depression and anxiety. The 
GHQ-12 gives a view of recent general mental health (in the past 4 weeks). GHQ-12 
total score ranges from 0 to 12 (binary scoring method, with the two least symptomat-
ic answers scoring 0 and the two most symptomatic answers scoring 1), with 3 being 
the threshold for psychiatric caseness. GHQ-12 total scores were considered only for 
the cases with at least 10 valid answers. In the case of missing values, the adjusted total 
score was calculated with the following algorhythm:
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•	 (score for questions answered/number of questions answered) x 12.
In addition, each GHQ-12-item score was calculated for all the participants with a 
valid answer for that item. The validity and reliability of the GHQ-12 have been wide-
ly demonstrated (Goldberg et al., 1976).
4.2.2.3 Composite international diagnostic interview (Cidi)
At the end of the health examination in the Health 2000 survey a structured diagnos-
tic interview (CIDI) developed by the World Health Organization (1990) was carried 
out. The CIDI is a comprehensive, fully structured diagnostic interview based on the 
definitions and criteria of the International Classification of Diseases 10 and DSM-IV. 
It is designed to be administered by trained lay interviewers, and it allows assessment 
of the presence, onset and recentness of psychiatric disorders (lifetime and in the 12 
months prior to the interview). It has been demonstrated to have excellent reliabili-
ty and adequate validity (Andrews & Peters, 1998). The Munich computerized version 
of the CIDI was used (Wittchen et al., 1998). For the purpose of this study, the focus 
was on alcohol abuse and dependence, MDE, MDD, dysthymic disorder, any anxiety 
disorder (i.e. panic disorder with or without agoraphobia, social phobia, phobic dis-
order not-otherwise-specified or generalized anxiety disorder). “Any current psychiat-
ric diagnosis” was defined as meeting the criteria for at least one full diagnosis in the 
last 12 months (excluding cases with missing data at one or more of the diagnoses in-
quired about).
4.2.2.4 Self-reported psychiatric diagnoses and psychotropic drug  
 use
No structured diagnostic interview was carried out in connection with the FIN-
RISK surveys. However, participants in FINRISK 2002 and 2007 were asked if they 
had received a psychiatric diagnosis in the previous year: “Has a doctor diagnosed 
or treated you for depression or other psychological illness during the past year (last 
12 months)?” Additionally, information on the use of any psychotropic drug during 
the previous year was available for FINRISK 1997 (“When was the last time you used 
sleeping pills/tranquillizers/antidepressants?”, with possible answers “during the past 
week”, “1–4 weeks ago”, “1–12 months ago”, “over a year ago” and “never”).
4.2.2.5 other psychological symptoms 
In the FINRISK surveys additional non-structured questionnaires were carried out 
to better assess psychological well-being. The presence of somatic and psychological 
symptoms was evaluated by asking the participants how often (“often, sometimes, not 
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at all”) in the previous month they had had one or more of 13 somatic and psychologi-
cal symptoms. Somatic symptoms included tachycardia, trembling of the hands, irreg-
ular heart rate, dizziness, headache and sweaty palms. Psychological symptoms includ-
ed feeling confused when having to do something quickly, feeling tense and nervous, 
having frightening thoughts, feeling exhausted and overstrained, having nightmares, 
depressiveness and insomnia. Only four symptoms (feeling exhausted, having night-
mares, insomnia and headache) were inquired about in FINRISK 2007. Additionally, 
the presence of depressed mood and anhedonia in the previous year was assessed via 
the questions “Have you during the last 12 months had a period of at least two weeks, 
when you have for the most time been low-spirited or depressed?” and “Have you dur-
ing the last 12 months had a period of at least two weeks, when you have for the most 
time lost interest in most things, such as hobbies, work, or other things that usually 
give you pleasure?”.
Abbreviations: Beck Depression Inventory-21 items (BDI-21), Composite International Diagnostic Interview (CIDI), 
General Health Questionnaire-12 items (GHQ-12). 
Health 2000
≥ 30 years
n=2310
18–29 years
n=913
BDI-24
n=1987, 86.0%
GHQ-12
n=2022. 87.5 %
CIDI
n=1859, 80.5%
GHQ-12
n=677, 74.2%
mean score
6.6
mean score
1.8
psychiatric diagnosis
n=348, 18.7%
mean score
1.5
Figure 7. Health 2000: mental health assessment (women).
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Abbreviations: Beck Depression Inventory (BDI), Beck Depression Inventory-13 items (BDI-13), Beck Depression Inven-
tory-21 items (BDI-21). 
4.2.3 Statistical analyses
Bivariate analyses were performed in all the studies to test the difference between 
groups, using “history of miscarriage” (Study I), “current use of OCs” and “current 
use of the LNG-IUS” (Study II and III), and “current use of HT” (Study IV) as group-
ing variables. The χ2 test was used to compare frequencies in tables and Fisher’s exact 
test was selected when expected frequencies were less than five. For continuous varia-
bles, comparisons of means were carried out using Student’s t-test. A two-tailed p-val-
ue <0.05 was considered significant.
The existence of partial correlations (age as a controlling variable) between men-
tal health and reproductive health variables was investigated in each study.
Multivariable analyses were performed, using linear and logistic regression mod-
els or generalized linear models, as appropriate, in order to identify the predictors that 
had a significant association with each mental health outcome variable. Predictors of 
interest included history (yes or no) and number (as a linear variable) of miscarriag-
FINRISK
Surveys
1987
6 somatic symptoms
7 psychological symptoms
past month
depressed mood
past year
anhedonia
past year
use of psychotropic drugs
past year
BDI-21
past 2 weeks
2002
6 somatic symptoms
7 psychological symptoms
past month
depressed mood
past year
anhedonia
past year
diagnosis of depression
past year
other psychiatric diagnosis
past year
NO BDI
2007
1 somatic symptom
3 psychological symptoms
past month
depressed mood
past year
anhedonia
past year
diagnosis of depression
past year
other psychiatric diagnosis
past year
BDI-13
past 2 weeks
Figure 8. FINRISK Surveys: mental health assessment.
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es (Study I), use (yes or no) of OCs or the LNG-IUS, and the length of time of use 
(Study II and III), and current use (yes or no) of HT (Study IV). Sociodemographic 
characteristics (age, professional status, marital status, educational level), reproductive 
features (bleeding pattern, number of (live) births, number of living children, expe-
rience of having given birth, lifetime infertility, reproductive status, history of hys-
terectomy) and current psychiatric diagnosis were entered in the models as control-
ling variables when appropriate, as described in the original publications. In study II 
the effects of third-generation (those containing desogestrel or gestodene) vs. second-
generation (i.e. those containing levonorgestrel, norgestimate or cyprotereone acetate) 
COCs were further analyzed through additional regression models where the type of 
OC was also entered as a predictor. Similarly, in study IV the possible effects of differ-
ent preparations (estrogen-only vs. combined preparations; oral estrogens vs. paren-
teral estrogens, and cyclic preparations vs. continuous combined preparations) were 
tested with three additional regression models. For this purpose, three categorical var-
iables (indicating the type of HT preparation) were created and alternatively entered 
in the regression models as further predictors.
Results are presented in terms of ORs and non-standardized B values with their 
95% CIs, indicating the factor by which the risk of a single symptom/disorder, or the 
score at a specific scale, is increased or decreased in the case of a history of miscar-
riage, or by each increasing miscarriage (Study I), in the case of OC or the LNG-IUS 
use, and with increasing duration of its use (Study II and III), and in the case of use of 
HT (Study IV). Cases with missing data concerning one or more variables were omit-
ted from the analyses.
Descriptive and multivariable analyses were performed using SPSS/PASW soft-
ware (version 18.0) (SPSS Inc., Chicago, IL, USA).
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5 Results
5.1 Main findings 
The main findings with regard to associations between mental health and reproduc-
tive features in women are presented in Table 6.
Miscarriage as a pregnancy outcome was related to a high prevalence of depres-
sive symptoms and disorder and more severe depressive/anxiety symptoms compared 
with other pregnancy outcomes. Moreover, the higher the number of miscarriages, the 
worse the current state of mood was and the higher the frequency of psychiatric di-
agnoses.
Furthermore, the results showed different patterns of associations between exoge-
nous hormones (hormonal contraception or HT) and mental health. Use of hormonal 
contraception was not associated with worse psychological status or depressive symp-
toms/disorders. However, the prevalence of depressive and anxiety disorders among 
women in connection with the menopausal transition was high, and in this group an 
Table 6. Summary of the main findings.
Study Results
Study I • Trend for higher prevalence of MDD, more severe depressive and anxiety symptoms in women 
with a history of miscarriage (compared to those without such a history)
• Associations between history of miscarriage and MDE and other depressive/anxiety symptoms
• Associations between number of miscarriages and psychiatric diagnoses (especially depression), 
GHQ-12 score and other depressive/anxiety symptoms
Study II • No association between OC use and BDI-21 or GHQ-12 score or CIDI diagnoses
• Negative associations between duration of OC use and some BDI-21 items
• Positive association between the duration of OC use and alcohol dependence
• No effects with regard to third- vs. second-generation COCs
• Negative associations between use and duration of use of the LNG-IUS and depressive symp-
toms (BDI-21)
Study III • Some negative associations between OC use and depressive symptoms
• No noteworthy associations between duration of use of OC and psychiatric symptoms
• No noteworthy associations between LNG-IUS use or its duration and psychiatric symptoms/dis-
orders
Study IV • High prevalence of psychopathology among perimenopausal and postmenopausal women us-
ing HT
• Associations between HT use and psychiatric diagnoses, in specific depression and anxiety dis-
orders
• Associations between HT use and depressive/anxiety symptoms
Abbreviations: Beck Depression Inventory-21 items (BDI-21), Combined Oral Contraceptive (COC), Composite In-
ternational Diagnostic Interview (CIDI), General Health Questionnaire-12 items (GHQ-12), Hormone Therapy 
(HT), Levonorgestrel-Intrauterine System (LNG-IUS), Major Depressive Disorder (MDD), Major Depressive Episode 
(MDE), Oral Contraceptive (OC).
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association between current HT use and worse psychological well-being or mental 
health has emerged.
5.2 Miscarriage and mental health (Study i)
Analyses were carried out among women aged 30 to 50 years in Health 2000 data, and 
25 to 50 years in FINRISK 2002 data, separately in the age groups ≤ 40 years and 41–
50 years. 
Of the 1936 participants in the Health 2000 survey, 1469 had had one or more 
pregnancies, and 351 (23.9%) of them had had one or more miscarriages (missing da-
ta for 1). The mean number of miscarriages was 1.4 (SD 1.4; range 1–20); two of the 
women with a history of miscarriage had had no live births (data missing for 31) and 
98 of them (27.9%) reported previous infertility.
Of the 2903 participants in the FINRISK survey, 2169 had had one or more preg-
nancies, and 462 (21.5%) of them had had one or more miscarriages (missing data 
16). The mean number of miscarriages was 1.4 (SD 0.7; range 1–6); 22 of the women 
with a history of miscarriage had had no births (data missing for 12), and 133 of them 
(29.7%, data missing for 14) reported previous infertility.
5.2.1 History of miscarriage
In the Health 2000 dataset a trend towards higher prevalence of MDD was found 
among women with a history of miscarriage (9.8% vs. 7.3%, NS); also, they had high-
er BDI-21 score (7.3 vs. 6.1, p<0.05) and GHQ-12 score (2.1 vs. 1.8, p<0.01) when 
compared with women without such a history. Similarly, in the FINRISK survey the 
prevalence of depression and other psychological disorders tended to be higher among 
women with a history of miscarriage (6.8% vs. 5.8%, NS; 1.7% vs. 1.3%, NS, respec-
tively).
After controlling for possible confounding factors in the multivariable analyses, 
a positive association was found between history of miscarriage vs. recent diagno-
sis of MDE (OR=1.830; 95% CI=1.005–1.334; p<0.05) only in the age group 41–50 
years, and vs. several BDI-21 and GHQ-12 items only in the age group 30–40 years 
(BDI “impaired working capability”: B=0.161, 95% CI=0.044–0.278, p<0.01; GHQ 
“strain”: B=0.192, 95% CI=0.048–0.335, p<0.01; “impaired enjoyment”: B=0.118, 
95% CI=0.015–0.220, p<0.05; “impaired problem coping”: B=0.110, 95% CI=0.022–
0.199, p<0.05) (Health 2000). However, no associations were found with any psy-
chiatric diagnosis in the previous year either in the Health 2000 (“any CIDI diagno-
sis”, 30–40 year group: OR=0.895, 95% CI=0.511–1.568, p>0.05; 41–50 year group: 
OR=1.364, 95% CI=0.862–2.159, p>0.05) or in FINRISK (“recent diagnosis of depres-
sion”, 25–40 year group: OR=0.710, 95% CI=0.455–1.109, p>0.05; 41–50 year group: 
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OR=0.999, 95% CI=0.487–2.050, p>0.05; “other recent psychiatric diagnosis”, 25–40 
year group: OR=3.664, 95% CI=0.865–15.516, p>0.05; 41–50 year group: OR=0.824, 
95% CI=0.173–3.932, p>0.05). Additionally, only a slightly significant negative asso-
ciation with recent anhedonia (OR=0.614; 95% CI=0.377–0.998; p<0.05), limited to 
the age group 25–40 years (FINRISK 2002), was detected. However, most of the signif-
icant associations were characterized by small effect sizes.
5.2.2 Number of miscarriages
After controlling for possible confounding factors (including the reproductive sta-
tus), the number of miscarriages was associated, among women aged 30–40 years 
in the Health 2000 study, with any current psychiatric CIDI diagnosis (OR=2.069; 
95% CI=1.116–3.835; p<0.05), as well as with GHQ-12 total score (B=0.636; 95% 
CI=0.047–1.224; p<0.05). Moreover, associations were observable between the 
number of miscarriages and several items of the BDI-21 (“feeling of looking ugly”: 
B=0.172, 95% CI=0.028–0.317, p<0.05; “tiredness”: B=0.123, 95% CI=0.013–0.233; 
p<0.05) and GHQ-12 (“impaired concentration”: B=0.112, 95% CI=0.014–0.209, 
p<0.05; “feelings of usefulness”: B=0.096, 95% CI=0.012– 0.180, p<0.05; “loss of self-
confidence”: B=0.165, 95% CI=0.003–0.327, p<0.05). With regard to the age group 
41–50 years, the number of miscarriages was positively associated with the BDI-21 
items “crying” (B=0.098; 95% CI=0.026–0.171; p<0.01), “irritability” (B=0.167; 95% 
CI=0.013–0.321; p<0.05) and “feeling of looking ugly” (B=0.158; 95% CI=0.062–
0.254; p<0.01), and negatively associated with the GHQ-12 item “feeling of overcom-
ing difficulties” (B=-0.120; 95% CI=-0.233–-0.007; p<0.05).
In the analyses from FINRISK 2002, number of miscarriages resulted to be as-
sociated with a recent diagnosis of depression only among women aged 41–50 years 
(OR=2.689; 95% CI=1.334–5.420; p<0.01), and with report of “frightening thoughts” 
(B=0.173; 95% CI=0.033–0.314; p<0.05) among women aged 25–40 years.
5.3 Hormonal contraception and mental  
 health (Studies ii and iii)
Studies II and III examined the possible associations between use of hormonal contra-
ception (OC and the LNG-IUS) and duration of their use vs. mental health and psy-
chological well-being. The data sources were Health 2000 for Study II and FINRISK 
1997, 2002 and 2007 for Study III. Figures related to OC and LNG-IUS use in the two 
studies are reported in Figures 9 and 10.
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18–54 years
n=3223
30–54 years
n=2310
18–29 years
n=913
OC
n=181 (9.5%)
LNG-IUS
n=212 (11.2%)
OC
n=332 (43.7%)
LNG-IUS
n=8 (4.5%)
mean length
11.6 years
mean length
5.1 years
mean length
4.9 years
Figure 9. Use of hormonal contraception and its duration among participants in Health 2000.
Abbreviations: Levonorgestrel-Intrauterine System (LNG-IUS), Oral Contraceptive (OC).
25–54 years
n=8586
OC
n=1225 (15.9%)
LNG-IUS
n=759 (9.7%)
mean length
8.6 years
mean length
5.2 years
Figure 10. Use of hormonal contraception and its duration among participants in FINRISK 
1997, 2002 and 2007.
5.3.1 oral contraceptives
Even though the prevalence of psychiatric disorders, in particular alcohol dependence 
(9.1% vs. 3.8%, p<0.01), but also MDE (10.4% vs. 7.5%, NS), MDD (9.1% vs. 7.3%, 
NS) and dysthymic disorder (3.6% vs. 1.7%, NS) tended to be slightly higher, a ten-
dency for lower BDI-21 score (5.9 vs. 6.5, NS) was found in OC users than in non-us-
ers in Health 2000. Different figures were found in FINRISK, with OC users having 
a lower prevalence of depression (5.5% vs. 7.8%, p<0.05) and other psychiatric dis-
orders (1.9% vs. 2.6%, NS), as well as less and less severe depressive symptoms (de-
pressed mood: 23% vs. 26%, p<0.05; anhedonia: 19% vs. 22%, p<0.01; BDI-21 score: 
6.8 vs. 8.4, p<0.01) than non-users.
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In multivariable analysis OC use only associated with the BDI item “feelings of 
worthlessness” (Health 2000) (B=-0.127; 95% CI=-0.238–-0.015; p<0.05). No other 
associations were found with BDI-21 and GHQ-12 score or current psychiatric diag-
nosis in the Health 2000. On the contrary, OC current use was negatively associated 
with BDI-13 (but not BDI-21) total score (B=-0.418; 95% CI=-1.791–-0.044; p<0.05) 
and some BDI items (“feelings of dissatisfaction”: B=-0.101, 95% CI=-0.202–-0.001, 
p<0.05; “feelings of worthlessness”: B=-0.093, 95% CI=-0.180–-0.005, p<0.05; “ir-
ritability”: B=-0.207, 95% CI=-0.368–-0.046, p<0.05; “lost interest in people”: B=-
0.068, 95% CI=-0.124–-0.013, p<0.05; and “lost appetite”: B=-0.040, 95% CI=-0.074– 
-0.007, p<0.05) in analyses from FINRISK surveys.
The duration of OC use was inversely associated with some of the BDI-21 items 
(“feelings of dissatisfaction”: B=-0.031, 95% CI=-0.052–-0.009, p<0.01; “irritabili-
ty”: B=-0.030, 95% CI=-0.055–-0.006, p<0.05; “lost interest in people”: B=-0.016, 
95% CI=-0.030– -0.002, p<0.05; “earlier waking”: B=-0.029, 95% CI=-0.053–-0.005, 
p<0.05; and “lost interest in sex”: B=-0.024, 95% CI=-0.043–-0.005, p<0.05), as well as 
with the diagnosis of MDD (OR=0.878; 95% CI=0.777–0.992; p<0.05), but positive-
ly related with higher risk of alcohol dependence (OR=1.485; 95% CI=1.134–1.944; 
p<0.01) and with more BDI-21 “worries about one’s health” (B=0.017; 95% CI=0.003–
0.031; p<0.05) (Health 2000). In FINRISK only a few significant associations, all char-
acterized by small effect sizes, emerged (“anhedonia in the previous year”: B=0.041, 
95% CI=0.005–0.079, p<0.05; “irregular heart rate”: B=0.009, 95% CI=0.001–0.018, 
p<0.05; and “insomnia”: B=0.009, 95% CI=0.002–0.017, p<0.05).
When testing for the effects of third vs. second generation COCs on mental health 
and psychological well-being, a significant difference emerged only in association with 
the GHQ item “impaired decision-making” (B=-0.120; 95% CI=-0.209–-0.031; p<0.01).
5.3.2 the LNG-iUS
In general, psychiatric disorders and symptoms tended to be less prevalent among us-
ers of the LNG-IUS compared with non-users (Table 7). 
In the multivariable analysis of the current use of the LNG-IUS and its duration, 
the main association was the one between LNG-IUS use and BDI-21 total score in 
Health 2000 (B=-0.988; 95% CI=-1.917–-0.059; p<0.05). Additional significant asso-
ciations, mostly characterized by small effect sizes, were detected between current use 
of the LNG-IUS and the BDI-21 item “earlier waking” (B=-0.221; 95% CI=-0.356–-
0.087, p<0.01) and the GHQ-12 item “impaired concentration” (B=-0.073; 95% CI=-
0.145–-0.002; p<0.05) (Health 2000). No significant associations emerged in analyses 
from FINRISK data. The duration of the LNG-IUS use associated with the GHQ-
12 item “strain” (B=-0.027; 95% CI=-0.052–-0.002; p<0.05) (Health 2000) and with 
the general symptom “confusion” (B=0.021; 95% CI=0.006–0.036; p<0.01) (FINRISK 
Surveys).
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5.4 Hormone therapy and mental health  
 (Study iV)
More than a quarter (n=406; 28.4%) of the 2640 women in the age group 40–74 years 
in the Health 2000 cohort, and 1464 (28.3%) of the 9449 women in the same age group 
from the FINRISK surveys reported having used HT during the month prior to the 
survey; 68 (16.7%) out of the 406 HT users in Health 2000 were perimenopausal. De-
scriptive analyses of HT users vs. non-users revealed a higher prevalence of psychiatric 
disorders (MDE and MDD: 9.8% vs. 4.2%, p<0.001; anxiety disorder: 8.1% vs. 4.6%, 
p<0.05) and depressive/anxiety symptoms (low mood: 26.7% vs. 21.1%, p<0.001; an-
hedonia: 23.1% vs. 19.8%, p<0.05; GHQ-12 mean score: 2.3 vs. 1.8, p<0.05) in peri-
menopausal and postmenopausal women currently under HT. No significant differ-
ence emerged with regards to alcohol dependence (2.3% vs. 1.8%, NS).
Current HT use was positively associated with the presence of any psychiatric 
diagnosis or use of any psychotropic drugs in the past 12 months (OR=1.435; 95% 
Table 7. Prevalence of psychiatric morbidity, and BDI-21, BDI-13 and GHQ-12 mean scores, 
among LNG-IUS users vs. nonusers. 
current LNG-IUS users LNG-IUS non-users
Health 2000
Any current psychiatric diagnosis 27 (13.6%) (n=198) 278 (18.7%) (n=1489)
Alcohol abuse 0 (n=200) 10 (0.7%) (n=1520)
Alcohol dependence 6 (3.0%) (n=200) 68 (4.5%) (n=1517)
Dysthimic disorder 3 (1.5%) (n=200) 29 (1.9%) (n=1524)
MDE 9 (4.5%) (n=200) 124 (8.1%) (n=1525)
MDD 9 (4.5%) (n=200) 119 (7.8%) (n=1525)
Anxiety disorder 9 (4.5%) (n=198) 93 (6.5%) (n=1493)
BDI-21 score (mean) 5.5** 6.6
GHQ-12 score (mean) 1.6 1.8
FINRISK
Recent depression diagnosis 46 (8.0%) (n=576) 342 (7.3%) (n=4656)
Other psychological illness 11 (1.9%) (n=577) 117 (2.5%) (n=4649)
Depressive symptoms during the past year 184 (24.4%) (n=755) 1788 (25.5%) (n=7010)
Anhedonia during the past year 143 (18.9%) (n=757) 1550 (22.1%) (n=6998)*
BDI-21 score (mean) 8.3 8.2
BDI-13 score (mean) 0.9 1.0
* χ2 test or t-test significant at p<0.05
** χ2 test or t-test significant at p<0.01
Abbreviations: Beck Depression Inventory-13 items (BDI-13), Beck Depression Inventory-21 items (BDI-21), Gener-
al Health Questionnaire-12 items (GHQ-12), Levonorgestrel-Intrauterine System (LNG-IUS), Major Depressive Dis-
order (MDD), Major Depressive Episode (MDE).
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CI=1.231–1.672; p<0.001), and in specific with a diagnosis of depression (Health 
2000: OR=2.459, 95% CI=1.484–4.074, p<0.001; and FINRISK: OR=1.444, 95% 
CI=1.111–1.877, p<0.01), as well as with anxiety disorders (Health 2000: OR=2.219, 
95% CI=1.319–3.732, p<0.01). Additionally, current use of HT was associated with 
reports of depressed mood in the past year (FINRISK: OR=1.222, 95% CI=1.040–
1.437, p<0.05) and with several depressive and anxiety symptoms (general symp-
toms: “feeling tense and nervous”: B=0.066, 95% CI=0.022–0.110, p<0.01; “frighten-
ing thoughts”: B=0.046, 95% CI=0.001–0.092, p<0.05; “nightmares”: B=0.049, 95% 
CI=0.012–0.085, p<0.01; “feelings of depression”: B=0.069, 95% CI=0.024–0.113, 
p<0.01; and “headache”: B=0.087, 95% CI=0.048–0.126, p<0.001; GHQ-12 “feel-
ings of depression”: B=0.102, 95% CI=0.007–0.197, p<0.05; GHQ-12 “unhappiness”: 
B=0.082, 95% CI=0.015–0.150, p<0.05; and BDI-21 “loss of interest in sex”: B=-0.187, 
95% CI=-0.281–-0.093, p<0.001). However, most of the associations were character-
ized by small effect sizes.
No significant differences emerged when testing whether different preparations 
(estrogen-only vs. combined preparations, oral estrogens vs. parenteral estrogens, 
combined cyclic preparations vs. combined continuous preparations) differently in-
fluenced mental health (data not shown).
65THL – Research 106 ♦ 2013
6 Discussion
In general, the results of this research are suggestive of a relationship between men-
tal health and reproductive health in women. Given the large sample size of the two 
population-based studies employed in this investigation (Health 2000 and FINRISK 
Surveys), and the consequent good generalization of the results, the findings provide 
a valuable contribution to the research in the field. However, the original hypotheses 
were not all completely proved.
6.1 Main findings
The key findings are those of an association between miscarriage as a pregnancy out-
come, as well as the use of exogenous hormones (hormonal contraception or HT), and 
women’s psychological well-being or mental health.
In detail, a history of miscarriage as well as the number of miscarriages were 
found to be associated with adverse outcomes in terms of psychological well-being or 
mental health. Also, a high prevalence of depressive and anxiety disorders in connec-
tion with the menopausal transition was detected. While the current use of HT was as-
sociated with worse psychological well-being or mental health, the use of hormonal 
contraception seemed not to relate to depressive symptoms or disorders or to other 
adverse psychological conditions.
6.2 Strengths and limitations
The main strength of this study is the use of nationwide, population-based samples, 
with a relatively good response rate: these factors allow a good generalization of the 
results. Also, the use of different diagnostic tools—mostly of proven high validity and 
reliability—to assess mental health, provides a guarantee that the results were not due 
to the properties of any single instrument.
However, the study has some limitations. The first stems from the cross-section-
al, partially retrospective design of the surveys. This precludes any causal relationship 
between the studied variables. Additionally, the use of different instruments to assess 
mental health in some cases precluded any reliable comparison of the results gained 
from the Health 2000 and FINRISK Surveys. In particular, mental health was better 
and more specifically assessed in the Health 2000 study.
Another limitation arises from the self-reported quality of the mood and psy-
chological well-being assessment both in the Health 2000 and FINRISK studies. Nev-
ertheless, the validity and reliability of the BDI-21, BDI-13 and GHQ-12 scales have 
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been widely demonstrated (Goldberg et al., 1976; Beck et al., 1988). Furthermore, in 
Health 2000, a structured interview with established validity and reliability (Wittchen 
et al., 1998), and administered by trained interviewers, was used to assess the presence 
of current psychiatric diagnoses. In the FINRISK Survey, mental health was assessed 
mostly via self-reported questions rather than through structured interviews or clin-
ical evaluations. However, even though self-reported psychiatric symptoms and diag-
noses may be biased by patients’ attitude or misperception, a good agreement has pre-
viously been reported (DeFife et al., 2010; Kelly et al., 2011) between the symptoms 
and levels of functioning reported by the patients and clinical evaluations, as well as 
clinical concept and definition of depression (and the criteria commonly included in 
the diagnostic tools).
Perhaps the main limitation is due to the fact that almost all the studied groups 
(OC-, LNG-IUS- and HT- users vs. non-users) were constituted by choice rather than 
chance. Therefore, it is plausible that the results were influenced by factors involved in 
deciding on hormonal contraception/HT use (mostly dependent on women’s own de-
cision or that of the health care provider). Even though most of the findings were con-
trolled for, several other factors may have biased the results.
Lastly, many of the significant associations detected in the analyses were accom-
panied by small effect sizes, probably as a consequence of the large sample size.
6.3 Miscarriage and mental health (Study i)
6.3.1 History of miscarriage
Results from the first study showed that a history of miscarriage is associated with de-
pressive and anxiety symptoms in women aged 30 to 50 years.
A miscarriage is known to be a stressful event for a woman, and it may be followed 
by a grief reaction resembling the one occurring after the death of a loved one (Brier, 
2008; Adolfsson & Larsson, 2010; Kersting & Wagner, 2012). In fact, a miscarriage is a 
true experience of loss. Additionally, it is characterized by its own features, since there is 
no possibility for concrete memories of the loved one: thus, the image of the loved one 
relies mostly on the mother’s mental representation and dreams (Brier, 2008).
The literature studying the possible mental health outcomes of a miscarriage has 
been broad, with quite inconsistent findings. Beutel et al. (1995) reported that the 
majority of the symptoms detected in the short-time following a miscarriage (most-
ly depressive and anxiety-related) were gradually attenuated at the six- and 12-month 
follow-ups (even though remaining more severe than in the general population). 
However, a subgroup of women developed a depressive (or grief-depressive) reaction 
(rather than a pure grief reaction), and they seemed to be at risk of a long-term de-
pressive status. Recently, in their longitudinal studies, Lok et al. (2010) and Sham et al. 
(2010) showed low psychological well-being and high levels of psychopathology (new 
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onset or recurrent psychiatric, especially depressive, disorders or symptoms) in wom-
en in the short term after a miscarriage. With regard to the duration of the sympto-
matic reaction following a miscarriage, most of the literature is consistent in claiming 
that it is normally self-limiting, and the symptoms subside within six to 12 months af-
ter the event (Nikcevic et al., 1999; Broen et al., 2005; Brier, 2008). However, it seems 
that some, more vulnerable women can be at higher risk of psychological distress, es-
pecially on the depressive side, even in the long term, and Lok et al. (2010) found that 
initially more distressed women had persisting elevated depressive symptoms, even at 
one year post-miscarriage. Moreover, young women experiencing a pregnancy loss, be 
it miscarriage or induced abortion, seem to have an increased risk of lifetime alcohol 
and substance use disorders and a higher risk of affective disorders when compared 
with women who had a live birth (Dingle et al., 2008).
The current study partly supports the hypothesis of a subgroup of more vulner-
able women who are at higher risk of psychiatric consequences even in the long term 
after the pregnancy loss. This is perhaps one of the first studies to analyze the relation-
ship between miscarriage and mental health using two large, population-based data-
sets, with detailed background information. Furthermore, it was possible to combine 
the data from the two studies, resulting in an extremely large sample, highly repre-
sentative of the Finnish population. In addition, while most of the research has gen-
erally focused on the short-term effects of a miscarriage (or other pregnancy losses), 
the possible long-term outcomes were also considered in the current work. Howev-
er, it must be remembered that this was a cross-sectional study with retrospective data 
collection. Therefore, no causal conclusion can be drawn. This is especially true since 
no information concerning the time when the miscarriage occurred or the onset of 
the psychiatric disorder/symptoms was available. Similarly, the social and psycholog-
ical conditions at the time of the miscarriage or in the immediate aftermath were al-
so unknown. These factors are recognized as influencing the reaction to a miscarriage, 
since the presence of marital and social support may help the grief process, while cer-
tain personality traits (e.g., neuroticism) and previous psychopathology (e.g., previ-
ous depressive episodes) may increase the risk of a complicated and long-lasting re-
action to the pregnancy loss. In addition to this, it warrants a mention that a range of 
life events, which possibly occurred in the time span between the index event and the 
current evaluation, could rather explain the current findings. In order to partially limit 
this potential bias, the study population was limited to women aged 30 (Health 2000) 
or 25 (FINRISK) to 50 years; moreover, separate analyses were conducted in two dif-
ferent age groups (≤ 40 years and 41–50 years). Different reactions to a past pregnancy 
loss were expected, given that these two groups were in different phases of their repro-
ductive lives. In fact, when looking at the main depressive symptoms and diagnoses, it 
seems that there was no significant relationship with a history of miscarriage either in 
younger or older women, with an increased risk of MDE only in women aged 41 to 50 
years. However, when looking at single item analyses, a number of associations, mostly 
indicative of a functional impairment as a consequence of a miscarriage, were evident 
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in the young group, though not among women older than 40 years. This could be ex-
plained by the different (psychological and physical) meaning that a pregnancy (and a 
pregnancy loss) may have in fertile aged women and in women approaching the men-
opausal transition. Even though all the analyses controlled for the reproductive status 
and for the number of (live) births, still it is possible that different patterns of asso-
ciations in the two age-groups are an expression of the overall different reproductive 
states of the group themselves.
6.3.2 Number of miscarriages
The results of this research also suggest that additional miscarriages may be associated 
with increasing severity of psychological impairment. This is in contrast with the re-
sults presented by some authors (Klier et al., 2000; Adolfsson & Larsson, 2010; Sham 
et al., 2010), who have found no increased risk of depressive reaction or other psychi-
atric symptoms in the case of a further miscarriage. Also, women presenting with high 
vs. low GHQ-12 and BDI-21 scores after a miscarriage seemed not to differ in terms of 
their obstetric history (i.e. previous miscarriages, previous induced abortions, histo-
ry of infertility and planned pregnancy) (Lok et al., 2010). However, some older stud-
ies (Friedman & Gath, 1989; Thapar & Thapar, 1992; Janssen et al., 1996) have shown 
more depressiveness and/or anxiety in women with a history of previous miscarriages. 
Women with a history of recurrent pregnancy losses were also found to have poorer 
quality of life and more depressive and anxiety symptoms during a subsequent preg-
nancy than pregnant women with no history of pregnancy loss (Couto et al., 2009). In 
contrast to previous research, the current study specifically focused on the association 
between the number of miscarriages (as a linear variable) and mental health status.
In this study, when looking at the single-item analyses, most of the significant 
items were those indicating self-criticalness (i.e., uselessness, negative self-view, loss 
of self-confidence), which in turn might lead to beliefs and feelings of (biological) 
inadequacy. Interestingly, these associations were detected in both age groups (even 
though they were more evident in young women), and irrespectively of reproductive 
status. This finding might have some clinical implications. Indeed, the theme of self-
criticalness and self-blame in relation to the cause of the miscarriage, especially when 
unknown, is frequently raised after a spontaneous pregnancy loss (Stratton & Lloyd, 
2008; Kersting & Wagner, 2012). Therefore, it could be hypothesized that a (psycho-) 
therapeutic approach to miscarrying women, especially those having multiple preg-
nancy losses, should address the question of self-inadequacy, self-criticalness and self-
blame, together with a revision of the causes of the miscarriage. 
Even though there are several limitations, these results emphasize the importance 
of assessing psychological well-being when counseling women with a history of mis-
carriage, as well as of inquiring into reproductive history when assessing psychopa-
thology in women.
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6.4 Hormonal contraception and mental  
 health (Studies ii and iii)
The results of Studies II and III showed no associations in terms of negative effects of 
hormonal contraception on mental health. Rather, they are suggestive of a potential 
beneficial influence of OCs, and in particular from long duration of use, on mood.
There is still quite a debate on the beneficial and potentially harmful side effects 
of hormonal contraception in relation to mental health, especially mood and anxiety 
symptoms/disorders. Even though some of the most recent studies did not find any in-
fluence of oral contraceptives in respect to mood (especially depressive) swings (Duke 
et al., 2007; O’Connell et al., 2007), nevertheless depression and depressiveness as well 
as mood changes in general are a common complaint among OC users, as well as a 
common reason for OC discontinuation (Oinonen & Mazmanian, 2002).
6.4.1 oral contraceptives
Women currently taking OCs tended to have a lower prevalence and less severe de-
pressive symptoms in comparison with women who were not taking them. No signif-
icant associations were detected with most of the BDI-21 and BDI-13 items, or with 
the risk of any psychiatric diagnosis. It could thus be concluded that current OC use 
has no significant detrimental effect on mood. By contrast, it may have some favora-
ble effects. However, being again a cross-sectional, partly retrospective study, no tem-
poral and causal relationship between the studied variables can be established. Indeed, 
there was no information on the timing of onset of possible psychiatric disorders/
symptoms. Additionally, a possible “healthy survivor effect” could not be excluded, i.e. 
that some of the non-OC users, with apparently more psychological distress, were past 
users that discontinued OCs because of side effects, including mood side effects. This 
would be in line with some literature reports showing that those women who develop 
mood side effects from OCs are those same women who are at increased risk of oth-
er hormone-related psychiatric disorders, such as postpartum (Bloch et al., 2005) and 
perimenopausal depression (Stewart & Boydell, 1993). Additionally, women vulnera-
ble to mood swings in association with OC seem to have specific “predisposing” per-
sonality traits (somatic anxiety, stress susceptibility) (Borgström et al., 2008). These 
results are all suggestive of a vulnerability to emotional side effects of OCs, where the 
vulnerability could be due to an increased hormonal sensitivity and/or due to specif-
ic personality traits. 
Interestingly, the results of the current study did not change when testing for the 
possible influence of third- vs. second-generation COCs. This is of particular interest, 
since most of the research on this topic has thus far focused on a specific COC com-
pound, or compared COCs with progestin-only pills or placebo (Böttcher et al., 2012), 
rather than on different generations of COCs. However, as noted by Böttcher et al. 
Mental health and reproductive health in women
70 THL – Research 106 ♦ 2013
(2012), the progestogenic component of the COCs, as well as the dose of the estrogen-
ic component, has rapidly changed in the recent decades, leading to possibly more ef-
fective and better tolerated preparations. Indeed, from the available literature it seems 
that second-generation COCs, with more androgenic characteristics, have a worse im-
pact on mood than third-generation preparations (Poromaa & Segebladh, 2012).
6.4.2 the LNG-iUS
Similar results were gained in respect to the LNG-IUS. To the best of my knowledge, 
this is the first study in which the relationship between mental health and use of the 
LNG-IUS has been directly addressed. To date, the research has mainly focused on sat-
isfaction rates and on the effectiveness of the LNG-IUS, mostly examining its possible 
side effects in general terms. However, even though the circulating concentrations of 
levonorgestrel are low in women using the LNG-IUS, the hormone released is rapid-
ly absorbed into the systemic circulation and is detectable in plasma 15 minutes after 
insertion of the device (Luukkainen, 1991). It would have therefore not been surpris-
ing if some women had experienced hormonal side effects, including the psychologi-
cal ones. Indeed, even though most of the studies report good effectiveness and high 
satisfaction rates (around 90%) among LNG-IUS users and with improved quality of 
life and psychological well-being (Skrzypulec & Drosdzol, 2008), some investigators 
have nevertheless reported only a 50% rate of satisfaction, with the most common-
ly reported reasons for discontinuation being bleeding, progestogenic adverse effects 
and abdominal pain (Daud and Ewies, 2008; Ewies, 2009). Similarly, in a Finnish sur-
vey on premature removal of the LNG-IUS, pelvic infections, pain, depression and re-
current vaginal infections were reported as rather uncommon reasons for discontinu-
ation (Backman et al., 2000). However, the findings from Studies II and III show that 
women currently using the LNG-IUS are not more depressed or in a worse psycholog-
ical condition than women not using it, suggesting that the LNG-IUS per se has a min-
imal effect, if any, on mental health.
6.4.3 duration of use of hormonal contraception
To date, only a few studies have been carried out on large samples and on a population 
basis to specifically investigate the influence of the duration of hormonal contracep-
tion use (Duke et al., 2007; Ryan et al., 2008), in particular of the LNG-IUS, on men-
tal health.
From the current research, it could be inferred that long term use of contracep-
tion, be it OC or the LNG-IUS, was not associated with increasing severity of psycho-
logical, especially depressive, symptoms or disorders. Rather, it seems that the longer 
the duration of current use of OCs is, the lower the scores in connection with many 
BDI-21 items, and the lower the risks of MDD are, in line with the findings of Duke 
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et al. (2007). Again these results could partly be an expression of a “healthy survivor 
effect”, with women experiencing no side effects being more likely to continue using 
the same preparation for a longer time. Nevertheless, a further important implication 
would be that those women who have encountered no psychological side effects in the 
early stages of use of hormonal contraception are not likely to develop them later dur-
ing their use. This consideration needs to be further tested in longitudinal prospec-
tive studies.
The only exception to this pattern was the association between the duration of 
current OC use and alcohol dependence. The question of the possible influence of 
sex steroids in general and hormonal contraceptives in particular on ethanol metab-
olism is still controversial (Warnet et al., 1984; King & Hunter, 2005). The findings of 
this study could be the result of possibly related confounding (e.g. psychosocial) fac-
tors. Indeed, it is possible that women with lifestyle factors associated with alcohol de-
pendence (e.g. risky sexual behavior or multiple partners) have been using (or have 
been advised to use) an effective contraceptive method (e.g. an OC) for a relatively 
long time. Also, because of the cross-sectional design of the study, the possibility that 
women with mental health problems or alcohol dependence have themselves chosen 
or have been advised to use the most effective methods of contraception (i.e. OCs and 
the LNG-IUS) for a long time, cannot be ruled out.
6.5 Hormone therapy in perimenopausal and 
 postmenopausal women (Study iV)
The findings from study IV did not support the original hypothesis of better psy-
chological well-being or mood in HT users, in particular in those using estrogen-on-
ly preparations. Indeed, a high prevalence of psychiatric disorders and symptoms, in 
particular depressive and anxiety ones, was found among HT users. Also, after con-
trolling for potential confounding factors in the regression analyses, an association 
between current use of HT and psychiatric morbidity was detected. These findings 
contrast with most of the literature on this issue. Indeed ET has been shown to be ef-
fective in alleviating depressive symptoms related to the menopausal transition, and 
it has been suggested as a therapeutic option, alone or as part of an augmentation 
strategy, for the treatment of perimenopausal depression. However, it warrants notice 
that only a combination of estrogen plus progestogens can be administered in wom-
en with an intact uterus, given the increased risk of endometrial hyperplasia in the 
case of unopposed estrogen administration (The Writing Group for the PEPI Trial, 
1996). The effects of progestogens on mood are quite questionable, and it seems that 
they may counteract the positive estrogenic effects and even induce depressive mood 
swings (Sherwin, 1999). Studies show that postmenopausal healthy women experi-
ence a worsening of mood during the estrogen-progestogen phase of their EPT cy-
Mental health and reproductive health in women
72 THL – Research 106 ♦ 2013
cles when compared with the estrogen-only phase (Björn et al., 2000). It is therefore 
possible that the progestogenic component of EPT may account for some psychologi-
cal side effects in a subgroup of women. Other studies have confirmed the hypothesis 
that different hormone combinations may exert different effects on mood and anxie-
ty (Cagnacci et al., 2004), suggesting that the choice of whether to use estrogen alone 
or a combination of estrogen plus progestogen, and in the latter case, which progestin, 
has to be carefully evaluated and adapted to the individual subject (Björn et al., 2000; 
Cagnacci et al., 2004). Additionally, past (but not current) use of HT was found to be 
associated with an increased risk of depression in elderly community-dwelling wom-
en, when compared with never-users (Ryan et al., 2008). However, Ryan et al.’s study 
did not take into account the effect of different HT compounds. A second study by the 
same research group and carried out on the same population found no association be-
tween (current or past) use of HT and anxiety disorders, irrespectively of the HT com-
pounds (Scali et al., 2009). In Study IV it was partly possible to control for the effects 
of different HT compounds and different routes of administration. However, this con-
trol was limited to a subset of the original sample, since this information was not avail-
able with respect to FINRISK 1997 and 2002, i.e., in the oldest datasets, where the use 
of older preparations is more likely.
The results of Study IV may also reflect the fact that HT users are probably a se-
lected population of women with more severe somatic and/or psychiatric illnesses, as 
well as with more disturbing climacteric symptoms. It could be speculated that these 
subjects are more prone to seek clinical help and have more contacts with the health 
care system, and are therefore more likely to be prescribed HT (Wilson et al., 1998; 
Bardel et al., 2002), as well as to have a psychiatric disorder detected and diagnosed by 
a clinician. In contrast, “healthier” women, with fewer climacteric complaints, proba-
bly see health professionals more seldom, and are therefore not prescribed HT.
Hence, even though these results do not allow establishing any causal and/or tem-
poral relationship between use of HT and recent psychological status, they highlight 
the high prevalence of psychiatric morbidity (either in terms of depressive and anxiety 
symptoms or disorders) in the perimenopausal and postmenopausal population. Al-
so, on the basis of these findings, using HT only for treating perimenopausal depres-
sion could not be recommended.
6.6 Clinical implications and future research
This study shows a close and multifaceted relationship between mental status and the 
reproductive life of women. Perhaps the main clinical correlate of these findings is once 
more the importance of considering gender-specific and individual approaches when 
assessing mental status and treating patients in general. Indeed, it is clear how psy-
chological well-being and psychopathology, but also life events, including reproductive 
events, and their perception differ between genders as well as inter-individually.
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In particular, the results of this study highlight the importance of considering re-
productive health and events when assessing psychological status and mental health 
in women. A history of miscarriage, especially of recurrent miscarriage, should be 
inquired into. Reciprocally, psychological well-being should be assessed when coun-
seling women with a history of miscarriage. As suggested by the results from single-
item analyses, the theme of self-criticalness and self-blame should be addressed during 
any (psycho-) therapeutic support to women following a miscarriage. Such programs 
should address the question of self-inadequacy, self-criticalness and self-blame, to-
gether with a revision of the causes of the miscarriage. Indeed, studies have found that, 
irrespective of the kind of treatment received, the amelioration of self-blame symp-
toms was more evident when a clear cause for the miscarriage was found (Nikcevic et 
al., 2007), and it is likely that awareness of the real causes of the miscarriage (including 
severe chromosomal aberrations, gene mutations, structural defects) may itself help in 
mitigating the reaction to a pregnancy loss.
Further clinical implications concern the users of hormonal contraception, who 
are often concerned with the possibility of mood side effects. Even though detrimental 
mood effects cannot be completely ruled out, nevertheless women could be reassured 
that only a minority of OC and LNG-IUS users are at risk of developing those mood 
side effects. This information should be provided to women willing to start or change 
their contraceptive method. Furthermore, the results showing no detrimental associa-
tions between mental health and duration of use of hormonal contraception may in-
directly suggest that the onset of mood or other psychological side effects is less likely 
in the long-term use of hormonal contraception. This hypothesis warrants further in-
vestigation in longitudinal prospective studies.
Lastly, the importance of considering the risk of depressive symptoms and disor-
ders in women entering the menopausal transition warrants further mention; in this 
group of women, on the basis of the results of Study IV, the use of HT alone for treat-
ing depressive and anxiety disorders cannot be recommended.
As this is a cross-sectional study which does not allow for drawing any causal con-
clusion, longitudinal studies are warranted to better study the relationship between 
mental health and reproductive health. In this respect, a currently ongoing study is 
aimed at further evaluating the relationship between contraceptive use and mental 
health in terms of alcohol and substance use, sleep disturbances, depressive and anx-
ious symptoms, deliberate self-harm and suicidal ideation and suicide attempts. The 
study participants are women aged 18 years or over who attend a gynecological (family 
planning) examination in order to start contraception or, if already using contracep-
tion, to attend an ordinary check-up. Attention will be focused on the type and com-
position of contraceptives as well.
In addition to this, future research could focus on the associations between men-
tal health and other reproduction-related variables. There is still quite a debate con-
cerning the possible influence of an induced abortion on mental health. A future study 
could focus on this issue by analyzing the data of the 913 young women (aged 18 to 
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29 years) who participated in the Health 2000 survey, and in particular of the young 
women who participated in the Mental Health in Early Adulthood in Finland study. 
Moreover, data from the follow-up study Health 2011 could be considered in the anal-
yses. Additional data concerning reproductive events, pregnancy outcomes and hos-
pitalizations could be gained through a linkage to the Medical Birth Register (number 
and outcome of births), the Abortion Register (induced abortions in hospital regis-
ter) and the records on spontaneous abortions treated in hospitals and in specialized 
health care.
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7 Conclusions
On the basis of these results, the questions asked previously could be answered.
I. Is a history of miscarriage related to further impairment of mood or psychological 
well-being? If so, is this impairment related to the increasing number of miscar-
riages?
Associations were found between history of miscarriage and depressive and anx-
iety symptoms and disorders. In addition, the results show an increasing risk for 
psychopathology with increasing numbers of miscarriages. Therefore, the origi-
nal hypothesis was supported by the results.
II. Does hormonal contraception have any influence on mental health or psychological 
well-being? Do different hormonal compounds differently influence mental health? 
Is the duration of use of hormonal contraception related to mental health?
Hormonal contraception, either OC or the LNG-IUS, does not have any detri-
mental influence on women’s mental health or psychological well-being; rather, it 
can have some beneficial influence. However, there seems to be no difference be-
tween different hormonal compounds (third- vs. second-generation pills). The 
effect of the duration of contraceptive use on mental health is less clear. Howev-
er, again it seems that long duration of use is not related to any detrimental, but 
rather a beneficial, influence on psychological status. Therefore, the original hy-
potheses were supported by these results where the effects of use and duration of 
contraception are concerned; it was not proven in respect to the effects of differ-
ent hormonal contraceptives.
III. Does hormone therapy in perimenopausal and postmenopausal women have any in-
fluence on mental health or psychological well-being? Does the relationship, if any, 
differ accordingly to different hormonal compounds?
Hormone therapy in perimenopausal and postmenopausal women is not relat-
ed to improved mental health; rather, it is associated with depressive and anxiety 
disorders, irrespective of the hormonal compounds or routes of administration. 
Therefore, the original hypothesis was not proven.
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